var title_f21_62_22496="Aspiration olecranon bursa";
var content_f21_62_22496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Aspiration of the olecranon bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is supine with the elbow flexed to 90 degrees and the forearm lying over the chest. Ethyl chloride or a comparable agent&nbsp;is applied to the skin for anesthesia. A 1.5 inch (3.75 cm), 16-gauge needle is inserted distally at the base of the bursa, nearly parallel to the ulna.&nbsp;0.5 mL of lidocaine is injected subcutaneously prior to aspiration of bursal fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22496=[""].join("\n");
var outline_f21_62_22496=null;
var title_f21_62_22497="Pediculosis pubis nits";
var content_f21_62_22497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis - nits and louse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light microscopy reveals two nits attached to a hair shaft (left). A louse is present on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22497=[""].join("\n");
var outline_f21_62_22497=null;
var title_f21_62_22498="Patient information: Jaundice in babies (The Basics)";
var content_f21_62_22498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15455\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/49/2833\">",
"         Baby getting light therapy in the hospital",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/23/1394\">",
"          Baby getting home light therapy for jaundice",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/43/17075\">",
"         Patient information: Breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/49/26386\">",
"         Patient information: Poor weight gain in babies and children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/38/2659\">",
"         Patient information: When a baby is born premature (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/61/37845\">",
"         Patient information: Common breastfeeding problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/45/16083\">",
"         Patient information: Jaundice in newborn infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Jaundice in babies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/jaundice-in-babies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H478055252\">",
"      <span class=\"h1\">",
"       What is jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Jaundice&rdquo; is the word doctors use when a baby&rsquo;s skin or white part of the eye turns yellow. Jaundice is common in newborn babies and can happen within days of a baby&rsquo;s birth. Babies are usually checked for jaundice for a few days after they are born.",
"     </p>",
"     <p>",
"      Jaundice happens when a baby has high levels of a substance called &ldquo;bilirubin&rdquo; in the blood. Jaundice is a sign that a doctor needs to do a blood test to check the baby&rsquo;s bilirubin level.",
"     </p>",
"     <p>",
"      Babies can have high bilirubin levels for different reasons. For example, some babies who breastfeed can get jaundice because they do not get as much breast milk as they need.",
"     </p>",
"     <p>",
"      It is important that a baby gets checked for jaundice to see if he or she needs treatment, because very high bilirubin levels can lead to brain damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055259\">",
"      <span class=\"h1\">",
"       How can I tell if my baby has jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can tell if your baby has jaundice by pressing one finger on your baby&rsquo;s nose or forehead. Then lift up your finger. If the skin is yellow where you pressed, your baby has jaundice.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055266\">",
"      <span class=\"h1\">",
"       What are the symptoms of jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Jaundice causes the skin and the white parts of the eyes to turn yellow. It often happens first in the face, but can spread to the chest, belly, and arms. It spreads to the legs last.",
"     </p>",
"     <p>",
"      Sometimes, jaundice can be severe. A baby with severe jaundice can have orange-yellow skin, or yellow skin below the knee on the lower part of the leg. A baby with severe jaundice might also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Be hard to wake up",
"       </li>",
"       <li>",
"        Have a high-pitched cry",
"       </li>",
"       <li>",
"        Be unhappy and keep crying",
"       </li>",
"       <li>",
"        Keep bending his or her body or neck backward",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055273\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your baby&rsquo;s jaundice is getting worse",
"       </li>",
"       <li>",
"        Your baby has symptoms of severe jaundice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055280\">",
"      <span class=\"h1\">",
"       Is there a test for jaundice?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A doctor can do an exam and a blood test to check for jaundice.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055287\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help the jaundice get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help your baby&rsquo;s jaundice get better, you can make sure your baby drinks enough. If you breastfeed your baby, make sure you breastfeed often and in the right way. If you feed your baby formula, make sure your baby drinks enough formula. If you are worried that your baby is not drinking enough, talk with your doctor or nurse.",
"     </p>",
"     <p>",
"      You can tell that your baby is drinking enough if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        He or she has 6 or more wet diapers a day",
"       </li>",
"       <li>",
"        His or her bowel movements change from dark green to yellow",
"       </li>",
"       <li>",
"        He or she seems happy after feeding",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some babies do not need any other treatment for their jaundice. This is because their bilirubin levels are only a little high, and the jaundice will get better on its own. But other babies will need treatment. Babies who need treatment might have higher levels of bilirubin or they might have been born early.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055294\">",
"      <span class=\"h1\">",
"       How is jaundice treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common treatment for jaundice is called &ldquo;light therapy.&rdquo; During light therapy, a doctor puts the baby under a special blue light (",
"      <a class=\"graphic graphic_picture graphicRef55964 \" href=\"UTD.htm?2/49/2833\">",
"       picture 1",
"      </a>",
"      ) or wraps a &ldquo;light blanket&rdquo; around him or her (",
"      <a class=\"graphic graphic_picture graphicRef73723 \" href=\"UTD.htm?1/23/1394\">",
"       picture 2",
"      </a>",
"      ). Babies who get light therapy are usually naked or wear only a diaper so that the light can shine on their skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478055301\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=see_link\">",
"       Patient information: Breastfeeding (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=see_link\">",
"       Patient information: Poor weight gain in babies and children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"       Patient information: When a baby is born premature (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"       Patient information: Jaundice in newborn infants (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       Patient information: Common breastfeeding problems (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/62/22498?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15455 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-31B8A52DC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22498=[""].join("\n");
var outline_f21_62_22498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055252\">",
"      What is jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055259\">",
"      How can I tell if my baby has jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055266\">",
"      What are the symptoms of jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055273\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055280\">",
"      Is there a test for jaundice?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055287\">",
"      Is there anything I can do on my own to help the jaundice get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055294\">",
"      How is jaundice treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478055301\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15455\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/49/2833\">",
"      Baby getting light therapy in the hospital",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/23/1394\">",
"       Baby getting home light therapy for jaundice",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=related_link\">",
"      Patient information: Poor weight gain in babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22499="Congenital syphilis evaluation and management";
var content_f21_62_22499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 635px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Evaluation and management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 615px; height: 697px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RPR: rapid plasma reagin; VDRL: Venereal Disease Research Laboratory; TP-PA:",
"     <em>",
"      Treponema pallidum",
"     </em>",
"     particle agglutination; FTA-ABS: fluorescent treponema antibody absorption; TP-EIA:",
"     <em>",
"      T. pallidum",
"     </em>",
"     enzyme immunoassay; MHA-TP: microhemagglutination test for antibodies to",
"     <em>",
"      T. pallidum",
"     </em>",
"     .",
"     <br/>",
"     * TP-PA, FTA-ABS, TP-EIA, or MHA-TP.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Test for human immunodeficiency virus (HIV) antibody. Infants of HIV-infected mothers do not require different evaluation or treatment.",
"     <br/>",
"     &Delta; A fourfold change in titer is the same as a change of 2 dilutions. For example, a titer of 1:64 is fourfold greater than a titer of 1:16, and a titer of 1:4 is fourfold lower than a titer of 1:16.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Women who maintain a VDRL titer 1:2 or less or an RPR 1:4 or less beyond 1 year after successful treatment are considered serofast.",
"     <br/>",
"     &sect; Complete blood cell (CBC) and platelet count; cerebrospinal fluid (CSF) examination for cell count, protein, and quantitative VDRL; other tests as clinically indicated (eg, chest radiographs, long-bone radiographs, eye examination, liver function tests, neuroimaging, and auditory brainstem response).",
"     <br/>",
"     &yen; Some experts would consider a single intramuscular injection of benzathine penicillin (Treatment Option 2), particularly if follow-up is not certain.",
"     <br/>",
"     &Dagger; Treatment (Option 1 or Option 2, above) with many experts recommending Treatment Option 1. If a single dose of benzathine penicillin G is used, then the infant must be fully evaluated, full evaluation must be normal, and follow-up must be certain. If any part of the infant's evaluation is abnormal or not performed, or if the CSF analysis is rendered uninterpretable, then a 10-day course of penicillin is required.",
"    </div>",
"    <div class=\"reference\">",
"     From: American Academy of Pediatrics. Syphilis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Copyright &copy; 2012 American Academy of Pediatrics. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22499=[""].join("\n");
var outline_f21_62_22499=null;
var title_f21_62_22500="Sodium polystyrene sulfonate: Patient drug information";
var content_f21_62_22500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium polystyrene sulfonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"     see \"Sodium polystyrene sulfonate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=see_link\">",
"     see \"Sodium polystyrene sulfonate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalexate;",
"     </li>",
"     <li>",
"      Kayexalate&reg;;",
"     </li>",
"     <li>",
"      Kionex&reg;;",
"     </li>",
"     <li>",
"      SPS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kayexalate&reg;;",
"     </li>",
"     <li>",
"      PMS-Sodium Polystyrene Sulfonate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium polystyrene sulfonate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2739723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low potassium levels or bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt diet (this drug has salt), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with liquid and drink. Do not mix with orange juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rectal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use enema rectally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11914 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22500=[""].join("\n");
var outline_f21_62_22500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023563\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023565\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023564\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023569\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023570\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023572\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023567\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023568\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023574\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=related_link\">",
"      Sodium polystyrene sulfonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/38/5733?source=related_link\">",
"      Sodium polystyrene sulfonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22501="Pathology electroanatomic map";
var content_f21_62_22501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correlation between electroanatomic map and pathological sections of infarcted heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows a section of the left ventricle in a patient with a subendocardial myocardial infarction (arrow). The superimposed colors in the reconstruction from an electroanatomic map (panel B) depict bipolar electrogram amplitude (BEA); purple indicates values &gt;6.1 mV; red indicates values &lt;2.1 mV. Beneath the reconstructed sections (panel C) are typical recordings of unipolar electrogram and derivatives, the unipolar electrogram amplitude (UEA) and slew rate (SR) and bipolar electrogram and amplitude from selected points at the core of the infarcted region (the distance between two white marks on the electrogram time scale denotes a 50-ms period).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 2001, 37:1590-7).",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22501=[""].join("\n");
var outline_f21_62_22501=null;
var title_f21_62_22502="Clidinium and chlordiazepoxide: Drug information";
var content_f21_62_22502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clidinium and chlordiazepoxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/50/38692?source=see_link\">",
"    see \"Clidinium and chlordiazepoxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Librax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorax&reg;;",
"     </li>",
"     <li>",
"      Librax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antispasmodic Agent, Gastrointestinal;",
"     </li>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct treatment of peptic ulcer; treatment of IBS: Oral: 1-2 capsules 3-4 times/day, before meals or food and at bedtime.",
"     <b>",
"      Caution:",
"     </b>",
"     Do not abruptly discontinue after prolonged use; taper dose gradually.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Clidinium bromide 2.5 mg and chlordiazepoxide hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Librax&reg;: Clidinium bromide 2.5 mg and chlordiazepoxide hydrochloride 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9480327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer before meals.",
"     <b>",
"      Caution:",
"     </b>",
"     Do not abruptly discontinue after prolonged use; taper dose gradually.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct treatment of peptic ulcer; treatment of irritable bowel syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Librax&reg; may be confused with Librium",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be inappropriate for use in geriatric patients (Quality of evidence: moderate [clidinium]/high [chlordiazepoxide]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, ataxia, confusion, anticholinergic side effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth, constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, blood dyscrasias, extrapyramidal symptoms, hepatic dysfunction, jaundice, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clidinium, chlordiazepoxide, or any component of the formulation; glaucoma; prostatic hyperplasia; benign bladder neck obstruction; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to potent anticholinergic adverse effects and uncertain effectiveness. In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as chlordiazepoxide), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of ChlordiazePOXIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F152526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An increased risk of congenital malformations has been associated with the use of minor tranquilizers during the 1st trimester. Because use of these drugs is rarely a matter of urgency, their use should be avoided during this period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F152523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken before meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F152521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Clidinium-Chlordiazepoxide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-5 mg (100): $156.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Librax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-5 mg (100): $975.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13361409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Chlorax (SG);",
"     </li>",
"     <li>",
"      Bralix (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IL, IQ, IR, JM, JO, KW, LB, LY, NL, OM, PR, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Braxidin (ID);",
"     </li>",
"     <li>",
"      Cliad (ID);",
"     </li>",
"     <li>",
"      Diporax (TW);",
"     </li>",
"     <li>",
"      Epirax (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Equirex (IN);",
"     </li>",
"     <li>",
"      Gastropax (EC);",
"     </li>",
"     <li>",
"      Klidibrax (ID);",
"     </li>",
"     <li>",
"      Kuanium (TW);",
"     </li>",
"     <li>",
"      Lerogin (CN);",
"     </li>",
"     <li>",
"      Librax (AE, AR, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CR, CY, DO, EG, ET, FI, FR, GH, GM, GN, GR, GT, GY, HK, HN, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NI, NL, OM, PA, PK, PT, QA, SA, SC, SD, SL, SN, SR, SV, SY, TH, TN, TT, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Libraxin (CN);",
"     </li>",
"     <li>",
"      Librocol (CH);",
"     </li>",
"     <li>",
"      Nirvaxal (IL);",
"     </li>",
"     <li>",
"      Poxidium (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Renagas (ID);",
"     </li>",
"     <li>",
"      Spasmoten (GT, NI)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/62/22502/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/62/22502/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8714 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-A590A08E48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22502=[""].join("\n");
var outline_f21_62_22502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152528\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152529\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152546\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152531\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152532\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682678\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682679\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152516\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9480327\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152517\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152550\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152544\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152519\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152507\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152541\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152511\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152526\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152512\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152522\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152536\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152523\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152521\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361409\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152524\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8714|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/50/38692?source=related_link\">",
"      Clidinium and chlordiazepoxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22503="Cystic fibrosis: Prenatal genetic screening";
var content_f21_62_22503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Prenatal genetic screening",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Katharine D Wenstrom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22503/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/62/22503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a multisystem disease affecting the pulmonary and digestive systems, sweat glands, and, in males, the reproductive tract. It is the most common monogenic disorder in Caucasians of Northern European heritage, with a prevalence of 1 in 2500 to 3300 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of prepregnancy or prenatal carrier screening is to identify couples at risk of having a child with classic CF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CYTOGENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis is an autosomal recessive disease. The gene causing CF has been identified on the long arm of chromosome 7 and encodes a protein called the cystic fibrosis conductance transmembrane regulator (CFTR); CFTR consists of 1480 amino acid residues and regulates epithelial cell chloride channel function. Over 1600 different mutations in the CF gene have been identified, but the vast majority occur at frequencies less than 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"      \"Cystic fibrosis: Genetics and pathogenesis\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Correlation with phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;&Delta;F508",
"    is the most common mutation causing classic CF in Caucasians, and W1282X is the most common gene causing classic CF in individuals of Ashkenazi Jewish heritage. Individuals who inherit other less common CF mutations may have an atypical CF presentation. The designation \"atypical CF\" refers to pulmonary disease without pancreatic insufficiency, or only one isolated feature of the disease, such as pancreatitis, liver disease, nasal polyps, or bilateral congenital absence of the vas deferens (CAVD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Atypical forms of CF have not been associated with specific mutations, except for CAVD, which is associated with the R117H mutation and the 5T or 7T allele or",
"    <span class=\"nowrap\">",
"     5T/5T",
"    </span>",
"    homozygosity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of clinical disease varies with the specific genetic mutations present, but for individuals who do not carry the",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    or W1282X alleles, there is no simple, predictable relationship between genotype and phenotype. The range of clinical expression likely reflects the degree to which protein function is changed by the mutation, modulation of the phenotype by other genes, and variation in susceptibility to environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RATIONALE FOR PRENATAL SCREENING AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of prepregnancy or prenatal carrier screening is to identify couples at increased risk of having a child with CF so that they can make an informed decision about pregnancy. Some carrier couples may choose to undergo an invasive diagnostic procedure during pregnancy to determine whether their fetus is affected, and some of these couples choose pregnancy termination to prevent the birth of an affected infant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/9\">",
"     9",
"    </a>",
"    ]. Some carrier couples may opt for preimplantation genetic diagnosis and the selective transfer of embryos without CF; but this requires in vitro fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/10\">",
"     10",
"    </a>",
"    ]. Other carrier couples may choose to use a donor egg or sperm or to avoid pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carrier couples who would not terminate an affected pregnancy may want prenatal testing so that they can plan for the birth of an affected child. Such planning is largely psychological, since the management of labor, delivery, and the neonatal period are not changed by the fetal diagnosis. Newborns with CF are usually asymptomatic; without neonatal screening for CF, the average age at diagnosis is 2.9 years. For this reason, waiting for neonatal testing is another reasonable option for carrier couples who definitely would not terminate an affected pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/11\">",
"     11",
"    </a>",
"    ]. All 50 states include CF in their newborn screening panel. Newborn screening has the obvious advantages of being less expensive and without the small risk of pregnancy loss associated with definitive prenatal testing. The Cystic Fibrosis Foundation offers information and support for families and individuals with CF (",
"    <a class=\"external\" href=\"file://www.cff.org/\">",
"     www.cff.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is one situation in which prenatal CF testing may be useful in ongoing pregnancies. Ten to 20 percent of fetuses with CF develop meconium ileus, which is virtually pathognomonic of the disease. Prenatal detection of hyperechoic fetal bowel (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36166?source=see_link\">",
"     \"Fetal echogenic bowel\"",
"    </a>",
"    ), followed by prenatal diagnosis of CF, makes meconium ileus likely; prenatal detection of meconium ileus may facilitate neonatal treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H11#H11\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Meconium ileus and distal ileal obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H59099793#H59099793\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THE SCREENING TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal CF screening was implemented in 2001, with subjects tested for a panel of what were believed to be the 25 most common CF mutations in the United States. If the mutation",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    or R117H was identified, the sample was tested for certain other mutations as part of a second tier reflex test (if",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    was identified, testing was performed for I506V, I507 V, F508C; if R117H was identified, testing was performed for",
"    <span class=\"nowrap\">",
"     5T/7T/9T).",
"    </span>",
"    Over the first two years of nationwide screening, the frequencies of the mutations in the initial screening panel were determined more accurately. As a result, two mutations (I148T and 1078delT) were eliminated from the standard or basic panel because their prevalence was &lt;0.1 percent or they did not cause classic CF (",
"    <a class=\"graphic graphic_table graphicRef65637 \" href=\"UTD.htm?35/38/36459\">",
"     table 1",
"    </a>",
"    ). The current standard panel consists of 23 mutations. In addition, the benefits of reflex testing were confirmed (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997, the National Institutes of Health recommended that CF screening be offered to all pregnant women seeking prenatal testing and couples actively planning pregnancy regardless of history \"to enable couples who wish to avoid the birth of a child with CF to do so\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/13\">",
"     13",
"    </a>",
"    ]. In 1998, representatives of the American College of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics, the National Human Genome Research Institute, and other professional organizations participated in a National Institutes of Health-sponsored workshop on the implementation of CF testing. With the help of guidelines and educational materials that were developed in three areas (clinical guidance and provider education, laboratory guidance and standards, and consumer education and informed consent), routine CF screening had become part of routine obstetric practice by 2001.",
"   </p>",
"   <p>",
"    In 2011, ACOG issued an updated committee opinion on CF screening, based in part on the screening experience of the previous 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/2\">",
"     2",
"    </a>",
"    ]. This opinion reiterated that, ideally, counseling and screening are performed before conception or in the first or early second trimester. It also stated that screening for CF should be offered to all patients contemplating pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Couples in whom one or both partners are Caucasian and of European or Ashkenazi Jewish descent are at highest risk of having an affected child because of the high carrier rate in these populations",
"    <span class=\"nowrap\">",
"     (1/24",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/25)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58715 \" href=\"UTD.htm?34/46/35563\">",
"     table 2",
"    </a>",
"    ). African Americans, Hispanics, and Asian Americans are at lowest risk (carrier rates",
"    <span class=\"nowrap\">",
"     1/61,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/58,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/94,",
"    </span>",
"    respectively). However, because mixed ethnicity is common, it is reasonable to offer CF carrier screening to all patients. Special consideration should be given to screening individuals with a personal or family history of CF (see below).",
"   </p>",
"   <p>",
"    It is often difficult for parents to make decisions about prenatal screening and testing because of the inability to reliably predict phenotype in all cases of positive tests, the inability of negative tests to reliably exclude disease in all cases, and the fact that individuals with CF born after 2000 are predicted to have a median survival of &gt;50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/14\">",
"     14",
"    </a>",
"    ]. For some patients, CF screening provides an opportunity to obtain important information about a current or future pregnancy, but for others, the information provokes significant and prolonged anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Women with a personal or family history of CF",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is universal consensus to offer prenatal CF",
"    <span class=\"nowrap\">",
"     screening/testing",
"    </span>",
"    to all pregnant women or women contemplating pregnancy who have a first-degree relative (son or daughter, sibling, mother, father) or second degree relative (aunt, uncle, nephew, niece, grandparent) with CF.",
"   </p>",
"   <p>",
"    It is useful to obtain the affected individual's medical records of the diagnostic tests performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a specific CF gene mutation(s) has been identified in the family, the woman can be screened for that particular mutation(s).",
"     </li>",
"     <li>",
"      If the affected family member has been studied, but his or her specific CF mutations could not be identified, restriction fragment length polymorphism analysis or gene sequencing may indicate whether or not the woman",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      her fetus) inherited the abnormal allele.",
"     </li>",
"     <li>",
"      If the affected individual or her medical records are unavailable, the woman can be screened for the standard panel of the most common CF mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If results from any of these testing methods show that the woman is a CF carrier, the father of the fetus should be tested for a panel of the most common CF mutations, including mutations specific to his ethnic group, if applicable. If he also has a family history of CF, he should be tested regardless of the results of his partner's carrier testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Couples with no family history of CF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with no personal or family history of CF may seek CF screening when planning pregnancy or in early pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. It is important that they understand the limitations of both positive and negative screening results. CF screening is most accurate for Caucasians of Northern European descent and for those of Ashkenazi Jewish heritage since a high proportion of disease in these groups is attributable to common identifiable mutations. Individuals of other ethnic backgrounds may not benefit from current CF screening tests because common CF-causing mutations have not been identified in their ethnic group, thus they might decide to forego testing (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Interpretation of test results'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic evidence of echogenic fetal bowel has been associated with CF, as well as other fetal disorders. The presence of echogenic bowel is another indication for parental screening. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36166?source=see_link\">",
"     \"Fetal echogenic bowel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCREENING STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, all testing within a family should be performed by the same laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1\">",
"     1",
"    </a>",
"    ]. The laboratory requisition should have information about the indication for testing,",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    background, and pertinent family history (including known familial mutations) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The least expensive, and probably most widely used, strategy is to test only the woman. Her risk of having an affected child can be calculated using her risk derived from testing and, if her partner is of Northern European heritage, assuming that he has a 1 in 25 risk (background risk) of being a carrier. Some patients will be reassured by this analysis and will not request further testing, especially if the only goal of testing is to determine the risk to the fetus.",
"     </li>",
"     <li>",
"      The next least expensive strategy is to test the woman's partner only if her test is positive, and if she desires a more accurate prediction of her child's risk than can be obtained using the partner's background risk (as described above). This is called serial screening.",
"     </li>",
"     <li>",
"      The most expensive but most accurate method is to test both members of the couple at the same time. This is called couple screening. This method works well for those who want the most accurate risk assessment, for couples who need to know their carrier status rapidly and cannot wait for serial screening, and for those whose goal is to identify families at risk (eg, to determine whether siblings of each partner might be at risk).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF TEST RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key to all CF screening is knowing which mutations to test for. This requires knowledge of the most common CF mutations in the United States and in individuals of different ethnic groups or heritages, or the specific mutations identified in an affected family member.",
"   </p>",
"   <p>",
"    The test report should indicate which mutations were screened for, and should include a post-test interpretation of the individual&rsquo;s residual risk of carrier frequency based on ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive screen &mdash; If the CF screen is positive, the individual should receive genetic counseling. If both partners carry a CF mutation, there is a one in four chance that their child will be affected. The severity of clinical disease in offspring varies as a function of the specific genetic mutations present; for CF mutations other than",
"      <span class=\"nowrap\">",
"       &Delta;F508",
"      </span>",
"      or W1282X (which are associated with classic CF), there is no simple, predictable relationship between genotype and phenotype.",
"     </li>",
"     <li>",
"      Negative screen &mdash; A negative screening test means only that the individual does not carry any of the CF mutations in the screening battery; a negative result thus reduces the likelihood",
"      <strong>",
"       BUT DOES NOT ELIMINATE",
"      </strong>",
"      the possibility that the individual is a CF carrier.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific mutations and carrier frequencies vary among different populations (",
"    <a class=\"graphic graphic_table graphicRef58715 \" href=\"UTD.htm?34/46/35563\">",
"     table 2",
"    </a>",
"    ). One in 25 Caucasian Americans of Northern European background carries a CFTR gene mutation; the most common mutation is designated",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    and accounts for 75 percent of all CF cases in this group. Native Americans also have a high CFTR gene mutation carrier frequency: 1 in 31 among the Pueblo people and 1 in 20 among the Zuni, although the",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    mutation is not common in these groups. The carrier frequency in Hispanics is 1 in 46.",
"   </p>",
"   <p>",
"    In individuals of Ashkenazi Jewish heritage, the carrier frequency is 1 in 24 and the most common mutations are W1282X (which accounts for 46 percent of all CF cases in this group),",
"    <span class=\"nowrap\">",
"     &Delta;F508,",
"    </span>",
"    G542X, 3849+10kb C&gt;T, and N1303K, which together account for 94 to 97 percent of CF cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In non-Ashkenazi Jews, carrier rates range from 1 in 24 to 1 in 29 if the patient's ancestors originated in Greece, Bulgaria, Georgia, or Libya, to 1 in 90 if the ancestors originated in Iran or Iraq.",
"   </p>",
"   <p>",
"    Unfortunately, the specific mutations responsible for CF in some groups are incompletely understood, and are unknown for many other ethnic or racial groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, many people are of mixed ancestry, making selection of mutations for testing even more difficult.",
"   </p>",
"   <p>",
"    Because it is not possible to screen for the more than 1600 known CFTR mutations during carrier testing, most CF testing laboratories screen for a specific panel of mutations with a frequency in the North American population of at least 0.1 percent (",
"    <a class=\"graphic graphic_table graphicRef65637 \" href=\"UTD.htm?35/38/36459\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/12\">",
"     12",
"    </a>",
"    ]. In two situations, additional \"reflex\" testing will also be done. If the test identifies",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     &Delta;F507,",
"    </span>",
"    the result could be a false positive due to variant codons at positions 506, 507, or 508. Accordingly, when",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     &Delta;F507",
"    </span>",
"    are identified, the sample is specifically tested for the variant codons I506V, I507V, and F508C to clarify the risk for the full CF phenotype. Similarly, the R117H mutation can only cause CF if it is on the same chromosome as a mutation called the 5T variant, located in a noncoding region of the CF gene,",
"    <strong>",
"     AND",
"    </strong>",
"    there is a CF mutation on the other chromosome. If there is a R117H mutation on one chromosome and the 5T variant on the other chromosome, or any of several other arrangements, and the fetus is male (",
"    <a class=\"graphic graphic_table graphicRef81257 \" href=\"UTD.htm?7/27/7611\">",
"     table 3",
"    </a>",
"    ), it will have congenital bilateral absence of the vas deferens (CBAVD). To resolve these two possibilities, when R117H is identified, additional testing for the",
"    <span class=\"nowrap\">",
"     5T/7T/9T",
"    </span>",
"    variants is done.",
"   </p>",
"   <p>",
"    The degree to which the risk of being a carrier is reduced after a negative test is determined by the number of mutations screened and the proportion of CF attributable to those mutations. As an example, if a Caucasian woman of Northern European descent does not carry the",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    mutation (which accounts for 75 percent of all CF cases in this population), her risk of being a CF carrier is reduced from 1 in 25 (the a priori risk based solely on ethnic origin) to 1 in 99 (",
"    <a class=\"graphic graphic_table graphicRef71503 \" href=\"UTD.htm?26/63/27643\">",
"     table 4",
"    </a>",
"    ). If she does not carry any of the most common mutations causing 90 percent of CF cases in her ethnic group, her risk is reduced to 1 in 246 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of having a child with CF is reduced, but not eliminated, when both members of the couple are tested and no CF mutations are identified. However, including both members' test results in the risk calculation magnifies the uncertainties inherent in screening. This concept is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef51620 \" href=\"UTD.htm?7/43/7868\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/17\">",
"     17",
"    </a>",
"    ], which shows the proportion of high risk couples (couples in which each member carries a CF gene) that are correctly identified according to the percentage of CF cases accounted for by the mutations in the screening panel. If each member of the couple is tested only for",
"    <span class=\"nowrap\">",
"     &Delta;F508,",
"    </span>",
"    which accounts for 75 percent of all CF cases, only 56 percent of couples who are truly at risk of having a child with CF will be correctly identified; if each member is tested for mutations that account for 90 percent of all CF cases (the screening panel that is most commonly used), only 81 percent of at-risk couples will be correctly identified.",
"   </p>",
"   <p>",
"    The mutations that comprise the current CF screening panel make CF screening most sensitive for Caucasians of Northern European descent and those of Ashkenazi Jewish heritage, in whom 88 and 94 percent of all CF cases, respectively, will be identified. Individuals of other ethnic backgrounds may not benefit from current CF screening, and thus might decide to forego the test (",
"    <a class=\"graphic graphic_table graphicRef55196 \" href=\"UTD.htm?10/10/10414\">",
"     table 6",
"    </a>",
"    ). Using the currently recommended 23 mutation panel, an Ashkenazi Jewish couple who both test negative have a 1 in 490,000 chance of having an affected offspring, but an Asian American couple that tests negative has a 1 in 134,000 chance of an affected offspring. If one member of the couple tests positive and the other tests negative, the risk of disease in offspring of Ashkenazi Jews and Asian Americans is",
"    <span class=\"nowrap\">",
"     1/1540",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/732,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete and accurate genetic counseling can be difficult to provide and time consuming. Consultation with a geneticist or provider with special expertise in CF testing is recommended for couples [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In whom either partner has CF or a positive screening test for CF",
"     </li>",
"     <li>",
"      With a family history of CF",
"     </li>",
"     <li>",
"      With an affected fetus",
"     </li>",
"     <li>",
"      In whom the male partner is infertile due to congenital bilateral absence or atresia of the vas deferens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of an expanded panel of CF gene mutations or gene sequencing may be appropriate in these situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FETAL TESTING AND PHENOTYPE PREDICTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing the potential parents for CF carrier status before they attempt conception is optimal, because foreknowledge of their carrier status allows them to make informed decisions about reproduction. Preimplantation genetic diagnosis is an option for carrier couples who want an unaffected child, but could not undergo pregnancy termination; however, it requires in vitro fertilization. A more common approach is to undergo fetal testing early in the pregnancy and then to make the reproductive choice in private; pregnancy termination may be easier, both psychologically and in terms of procedure-related risks, before the pregnancy has become obvious to others and before the woman has felt fetal movement.",
"   </p>",
"   <p>",
"    If one parent is screen positive and the other is screen negative (and the family history is negative for CF), fetal testing is not useful, as it will not be possible to distinguish a carrier fetus from an affected fetus with an unidentifiable CF mutation. De novo CFTR mutations in a fetus have not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If both members of a couple are CF carriers, the next step is to test the fetus. The CF gene can be evaluated using DNA isolated from chorionic villus cells (obtained at 11 to 14 weeks of gestation), amniocytes (obtained at &ge;15 weeks of gestation), or fetal blood (obtained at &ge;20 weeks of gestation).",
"   </p>",
"   <p>",
"    If the fetus is homozygous for a CF gene mutation, the parents should be given complete information about the likely CF phenotype so that they can make an informed decision about the future of the pregnancy. In the setting of a family history of CF in which at least one of the CF mutations inherited by the fetus is identical to that carried by the affected family member, the fetus is predicted to have a phenotype similar to that of the affected relative. This is especially true if the fetus has inherited at least one of the two most common CF mutations",
"    <span class=\"nowrap\">",
"     (&Delta;F508",
"    </span>",
"    or W1282X), which are associated with the classic, severe phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. However, the second mutation can also have important effects on phenotype.",
"   </p>",
"   <p>",
"    If the fetus inherits other, less common mutations, or if limited medical information about the affected relative is available, phenotype prediction is difficult.",
"   </p>",
"   <p>",
"    Several CF mutations are fairly consistently associated with pancreatic insufficiency",
"    <span class=\"nowrap\">",
"     (&Delta;F508,",
"    </span>",
"    W1282X, G542X, 1717GA, N 1 303K), pancreatic sufficiency (R1 17H, R334W, T3381, R347P, etc.), and congenital absence of the vas deferens",
"    <span class=\"nowrap\">",
"     (&Delta;F508,",
"    </span>",
"    R1 17H, 5Tvar, 7Tvar) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/5,18-20\">",
"     5,18-20",
"    </a>",
"    ]. However, because 95 percent of the morbidity and mortality of CF is attributable to pulmonary disease, predicting pulmonary function in fetuses homozygous for CF mutations is of prime importance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/19\">",
"     19",
"    </a>",
"    ]. Unfortunately, aside from the",
"    <span class=\"nowrap\">",
"     &Delta;F508",
"    </span>",
"    and W1282X mutations, very poor genotype-phenotype correlation exists for this trait. Furthermore, cases have been reported in which two individuals inherited identical CF mutations, but had very different degrees of pulmonary pathology. This suggests that environmental influences or varying treatment regimens may play a role in phenotype expression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22503/abstract/5\">",
"     5",
"    </a>",
"    ]. Prenatal prediction of the fetus' ultimate risk of having liver disease or diabetes mellitus, the age at which CF symptoms occur, its ultimate",
"    <span class=\"nowrap\">",
"     weight/height",
"    </span>",
"    ratio, or its sweat chloride levels is not currently possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of prepregnancy or prenatal carrier screening is to identify couples at risk of having a child with classic cystic fibrosis (CF). Some couples will use their screening results to prevent the birth of an affected infant, while others will use the information to plan for the birth of an affected child. Because obstetric management is not changed by the prenatal diagnosis of CF, couples who would not terminate an affected pregnancy may elect to wait and have newborn CF screening. Newborn screening would also allow neonatal intervention, in the rare event that it became necessary. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rationale for prenatal screening and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for CF should be",
"      <strong>",
"       offered",
"      </strong>",
"      to the following patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Individuals with a family history of CF",
"     </li>",
"     <li>",
"      Reproductive partners of individuals who have CF",
"     </li>",
"     <li>",
"      Couples in whom one or both partners are Caucasian and of European or Ashkenazi Jewish descent and who are planning a pregnancy or seeking prenatal care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The test should be",
"    <strong>",
"     made available",
"    </strong>",
"    to women of other ethnic groups, who have been informed of the detectability of CF in individuals of their heritage. Because mixed ethnicity is common, it is reasonable to offer CF carrier screening to all patients who do not identify with a single ethnic group. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Candidates for screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening is usually sequential (the woman is tested first; her partner is tested only if she is a carrier), but may be couple based (both partners are tested at the same time). CF testing laboratories will screen for a specific panel of the 23 to 32 most common CF mutations in the United States (",
"      <a class=\"graphic graphic_table graphicRef65637 \" href=\"UTD.htm?35/38/36459\">",
"       table 1",
"      </a>",
"      ). The basic panel of 23 mutations accounts for almost 90 percent of detectable mutations in nonHispanic North American Caucasians. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening strategies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Interpretation of test results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the CF screen is positive, the individual should receive genetic counseling. If both partners carry a CF mutation, there is a one in four chance that their child will be affected. The severity of clinical disease in offspring varies as a function of the specific genetic mutations present, but when the fetus inherits CF mutations other than",
"      <span class=\"nowrap\">",
"       &Delta;F508",
"      </span>",
"      or W1282X, there is no direct relationship between genotype and phenotype, making the phenotype difficult to predict. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Interpretation of test results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A negative screening test means only that the individual does not carry any of the CF mutations in the screening battery; a negative result thus reduces the likelihood,",
"      <strong>",
"       but does not eliminate",
"      </strong>",
"      the possibility, that the individual is a CF carrier. The degree to which the risk of being a carrier is reduced after a negative test is determined by the number of mutations screened for and the proportion of CF attributable to those mutations. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Interpretation of test results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If both members of a couple are determined to be CF carriers, the next step is to test the fetus. In the setting of a family history of CF in which at least one of the CF mutations inherited by the fetus is identical to that carried by the affected family member, the fetus may be predicted to have a phenotype similar to that of the affected relative. If the fetus inherits other, less common mutations, or if limited medical information about the affected relative is available, phenotype prediction is difficult. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fetal testing and phenotype prediction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.acmg.net (accessed March 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/2\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gynecol 2011; 117:1028.",
"     </a>",
"    </li>",
"    <li>",
"     Cystic Fibrosis Mutation Database. Available at www.genet.sickkids.on.ca/cftr/. (Accessed march 23, 2009).",
"    </li>",
"    <li>",
"     www.geneclinics.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/5\">",
"      Ferrari M, Cremonesi L. Genotype-phenotype correlation in cystic fibrosis patients. Ann Biol Clin (Paris) 1996; 54:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/6\">",
"      Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/7\">",
"      Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/8\">",
"      Chill&oacute;n M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995; 332:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/9\">",
"      Castellani C, Picci L, Tamanini A, et al. Association between carrier screening and incidence of cystic fibrosis. JAMA 2009; 302:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/10\">",
"      Fragouli E. Preimplantation genetic diagnosis: present and future. J Assist Reprod Genet 2007; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/11\">",
"      Comeau AM, Accurso FJ, White TB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007; 119:e495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/12\">",
"      Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/13\">",
"      Acupuncture. NIH Consens Statement 1997; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/14\">",
"      Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/15\">",
"      Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997; 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/16\">",
"      Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992; 50:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/17\">",
"      Elias S, Annas GJ, Simpson JL. Carrier screening for cystic fibrosis: implications for obstetric and gynecologic practice. Am J Obstet Gynecol 1991; 164:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/18\">",
"      Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med 1990; 323:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/19\">",
"      Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22503/abstract/20\">",
"      Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 1993; 329:1308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 463 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22503=[""].join("\n");
var outline_f21_62_22503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CYTOGENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Correlation with phenotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RATIONALE FOR PRENATAL SCREENING AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THE SCREENING TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CANDIDATES FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Women with a personal or family history of CF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Couples with no family history of CF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCREENING STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INTERPRETATION OF TEST RESULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic consultation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FETAL TESTING AND PHENOTYPE PREDICTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/38/36459\" title=\"table 1\">",
"      Cystic fibrosis screening panel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/46/35563\" title=\"table 2\">",
"      CF carriers by ethnic origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/27/7611\" title=\"table 3\">",
"      Interpretation reflex test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/63/27643\" title=\"table 4\">",
"      CF risk after mutation analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/43/7868\" title=\"table 5\">",
"      CF risk couples based screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/10/10414\" title=\"table 6\">",
"      Overview of prenatal CF screening",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36166?source=related_link\">",
"      Fetal echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22504="AIDS-related cytomegalovirus gastrointestinal disease";
var content_f21_62_22504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related cytomegalovirus gastrointestinal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22504/contributors\">",
"     Mark A Jacobson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22504/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22504/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/62/22504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) gastrointestinal (GI) disease is an uncommon but serious complication of AIDS. Prior to the availability of highly active antiretroviral therapy (HAART), CMV GI disease occurred in up to 5 percent of patients with AIDS, primarily in those with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the incidence of CMV GI disease has decreased substantially since HAART became available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other CMV-related diseases in HIV-infected patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7623?source=see_link\">",
"     \"AIDS-related cytomegalovirus neurologic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .) The pathogenesis of CMV is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for CMV disease include viremia and advanced immunosuppression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of CMV in blood (as measured by culture, CMV DNA amplification, or antigen detection) was demonstrated to be a risk factor for the subsequent development of invasive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most cases of CMV disease occur in the setting of advanced immunosuppression, with CD4 counts less than 50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV gastrointestinal disease was first reported as a manifestation of AIDS in 1983. In early case series, patients generally died within several months without CMV-specific treatment, and hemorrhage or perforation often complicated the course of this disease. Even with the advent of antiviral drugs for the treatment of CMV infection, the prognosis for patients with gastrointestinal disease was poor prior to the availability of HAART. As an example, the median survival was reported to be only four months after the diagnosis of CMV colitis and only eight months after CMV esophagitis, even with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impact of HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of AIDS patients with CMV gastrointestinal disease is much improved in the era of HAART. Most cases of end organ disease occur in patients who are not receiving or have failed HAART.",
"   </p>",
"   <p>",
"    A large multicenter prospective cohort study in Europe was designed to examine the incidence of CMV disease and the rate of survival after diagnosis in patients with AIDS in the pre- and post-HAART eras [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/9\">",
"     9",
"    </a>",
"    ]. A total of 707 of 8,556 patients had CMV disease at recruitment and follow-up: 449 with retinitis, 190 with extraocular disease, and 58 with both. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 190 cases of extraocular disease, 66 percent involved the gastrointestinal tract and 17 percent involved the central nervous system.",
"     </li>",
"     <li>",
"      Of patients who had a CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      1.8 percent of those on HAART developed CMV disease compared to 11 percent on dual therapy and 14 percent without treatment.",
"     </li>",
"     <li>",
"      Mortality significantly declined in the post-HAART era (from 79 to 42 percent).",
"     </li>",
"     <li>",
"      Initiation of HAART after CMV diagnosis was associated with a 37 percent decline in mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common gastrointestinal sites of CMV involvement are the esophagus and the colon. Symptom presentation depends on the anatomic location of the infection. The approach to the evaluation of the following clinical entities are discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV esophagitis presents with fever, odynophagia, and nausea, and is occasionally accompanied by substernal burning pain.",
"   </p>",
"   <p>",
"    CMV most commonly causes multiple ulcers at the lower esophageal sphincter, but diffuse esophagitis is also described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of esophagitis and its evaluation and management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV gastritis presents with substernal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epigastric burning pain. Gastrointestinal hemorrhage is a rare manifestation of CMV disease at this site [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of gastritis and its evaluation and management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=see_link\">",
"     \"Evaluation of abdominal pain in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Enteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV infection of the small bowel accounts for approximately 4 percent of all CMV infections of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/12\">",
"     12",
"    </a>",
"    ]. CMV enteritis is manifested clinically by generalized abdominal pain and diarrhea. Rare reports of dyspepsia and ileal perforation secondary to CMV have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis and management of the patient with suspected enteritis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=see_link\">",
"     \"Evaluation of abdominal pain in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV colitis is the second most common manifestation of end organ disease after CMV retinitis. CMV colitis is associated with low-grade fever, weight loss, anorexia, malaise, and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/15\">",
"     15",
"    </a>",
"    ]. Explosive watery diarrhea is common, but can be sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5\">",
"     5",
"    </a>",
"    ]. Symptoms that suggest large bowel involvement include frequent small volume diarrhea, tenesmus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematochezia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/16\">",
"     16",
"    </a>",
"    ]. Extensive mucosal hemorrhage and perforation can be life-threatening complications.",
"   </p>",
"   <p>",
"    The differential diagnosis of colitis in the HIV-infected patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV can rarely cause large, painful ulcers of the mouth, pharynx, or anus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/17\">",
"     17",
"    </a>",
"    ]. In the oropharynx, these ulcers may be mistaken for aphthous ulcers or herpes simplex erosions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CMV should be suspected when the initial evaluation is unrevealing for more common causes of gastrointestinal disease in AIDS patients. It should also be noted that multiple simultaneous pathogens can be identified in the setting of severe immunocompromise.",
"   </p>",
"   <p>",
"    CMV gastrointestinal disease is most accurately diagnosed by a triad of the cardinal symptoms, visualization of mucosal ulcers or erosions, and histologic evidence of tissue destruction with presence of viral inclusion bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As an example, CMV esophagitis is most convincingly diagnosed by the presence of fever and odynophagia in the setting of extensive, large, shallow ulcers or erosions seen by endoscopy in the distal esophagus. A confirmatory biopsy demonstrates tissue destruction and the presence of intranuclear or intracytoplasmic inclusion bodies in the endothelial cells with an inflammatory reaction at the edge of the ulcer. The presentation of CMV colitis can vary endoscopically from punctuate and superficial erosions, to deep ulcerations and necrotizing colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5,20\">",
"     5,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral culture of mucosal biopsies for CMV does not establish a diagnosis of CMV disease since patients with advanced immunosuppression may have viremia in the absence of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/19,21\">",
"     19,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV viremia can be detected by polymerase chain reaction (PCR), antigen assays, or blood culture. Caution should be exercised however regarding the detection of CMV, since viremia may be present in the absence of invasive disease; conversely CMV may not be detected by any of these methods in the setting of end-organ disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presence of CMV antibody is clinically not useful in this setting except when the serology is negative, since most patients have invasive disease based on reactivation of latent infection and not primary infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV gastrointestinal disease is characterized histologically by mucosal inflammation, tissue necrosis, and vascular endothelial involvement. Characteristically, cytomegalic cells (large cells containing eosinophilic intranuclear and frequently basophilic intracytoplasmic inclusions) are present in mucosal biopsies stained with hematoxylin and eosin (",
"    <a class=\"graphic graphic_picture graphicRef52984 \" href=\"UTD.htm?33/6/33893\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/22\">",
"     22",
"    </a>",
"    ]. Without effective antiviral treatment, the tissue destruction increases and can lead to hemorrhage or perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ophthalmologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extraocular CMV disease often have concurrent CMV retinitis. As a result, any patient diagnosed with CMV gastrointestinal disease should begin formal ophthalmologic screening for retinitis, with examinations repeated at six-month intervals until the patient's absolute CD4 count has been restored to &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    by antiretroviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CMV gastrointestinal disease involves induction therapy for three to six weeks; whether maintenance treatment is also needed is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy and toxicity of approved treatments for CMV retinitis have been firmly established as the result of many randomized prospective trials, there have been few double-blind placebo-controlled trials of CMV treatment for gastrointestinal disease. There are more data to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for CMV colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef80535 \" href=\"UTD.htm?23/41/24221\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70634 \" href=\"UTD.htm?4/25/4509\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 62 patients with biopsy-proven CMV colitis were randomly assigned to receive a 14-day course of intravenous (IV)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or placebo every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/26\">",
"       26",
"      </a>",
"      ]. In this initial trial, the benefits of ganciclovir were modest resulting in maintenance of body weight and decreased extracolonic CMV disease as compared to placebo; however diarrhea persisted in both groups. The authors suggested that a longer treatment duration may be needed.",
"     </li>",
"     <li>",
"      In a second trial, 48 patients with CMV gastrointestinal disease were randomly assigned to IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      BID) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      (90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      BID) for two weeks with the option to continue therapy for an additional two weeks if the GI symptoms did not resolve [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/27\">",
"       27",
"      </a>",
"      ]. Mucosal healing was demonstrated in a similar number of patients in both groups by endoscopy (85 and 83 percent, respectively). Inclusion bodies disappeared from follow-up mucosal biopsies in 73 percent of the patients in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    are effective for the initial management of CMV gastrointestinal disease. The choice of drug may be made on the basis of side effects. As an example, we prefer ganciclovir because of the cost, inconvenience, and renal side effects associated with foscarnet. However, in patients with pre-existing severe thrombocytopenia, foscarnet may be the better initial agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of induction therapy is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5,28\">",
"     5,28",
"    </a>",
"    ]. In one of the studies cited above, approximately 40 percent of patients required more than two weeks of therapy to maximize their clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/27\">",
"     27",
"    </a>",
"    ]. In a second study, disappearance of CMV inclusion bodies occurred after three weeks of therapy, while complete healing of erosions took six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The consensus of clinical experts is that patients with CMV gastrointestinal disease should receive three to six weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/5,19,28,29\">",
"     5,19,28,29",
"    </a>",
"    ]. We generally agree with this recommendation, although the duration in part depends upon the rapidity of symptom resolution and ability to tolerate therapy. As an example, a patient who responds symptomatically within one week of treatment may only need three to four weeks of induction therapy, while a patient who is slower to respond should be treated for the full six weeks if it is tolerated. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Patient monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early pre-HAART era, the only treatments available were via the intravenous route. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is a valine ester of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , and is rapidly absorbed and hydrolyzed to ganciclovir, resulting in high oral bioavailability. Although valganciclovir has not been studied in the treatment of gastrointestinal CMV disease, it has been proven to be effective therapy for CMV retinitis with similar toxicity to intravenous ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Patient monitoring'",
"    </a>",
"    below.) Valganciclovir at a dose of 900 mg provides a daily exposure of ganciclovir comparable to that of intravenous ganciclovir at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have resolution of their initial clinical symptoms (eg, diarrhea or odynophagia), we prefer to complete their induction therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (900 mg twice daily) to decrease the risk of catheter related line infections. We recommend NOT using valganciclovir as initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Initiation of HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of HAART is an important adjunct to the treatment of opportunistic infections. In patients with CMV retinitis, sustained CD4 T-cell recovery is associated with more durable remissions and a decreased risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. We suspect that these benefits also extend to the treatment of CMV gastrointestinal disease.",
"   </p>",
"   <p>",
"    HAART initiation should begin after resolution of the initial presenting symptoms (eg, diarrhea or odynophagia). Although HAART has been associated with complications of CMV retinitis related to immune recovery, we are unaware of any reports related to gastrointestinal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universal agreement about the use of maintenance therapy in CMV gastrointestinal tract disease. One study in the pre-HAART era did not suggest benefit of maintenance therapy compared to no maintenance in terms of relapse or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there are little data on the management of gastrointestinal CMV disease in the post-HAART era, and maintenance therapy is not recommended by the IDSA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the availability of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has simplified the management of CMV disease, and at doses used for maintenance therapy the drug is reasonably well tolerated. As a result, we suggest maintenance therapy with valganciclovir (900 mg per day) in patients who have had a relapse of CMV gastrointestinal disease. Reinduction therapy is required before maintenance therapy can begin. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Induction therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend that all patients who have had anti-CMV maintenance therapy discontinued should undergo regular monitoring, including annual ophthalmologic evaluations, for detection of CMV relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Salvage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following options are available for patients who fail to respond to their initial anti-CMV therapy, or who relapse despite chronic maintenance therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Switching to the alternative agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      if they were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      initially or vice versa) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination therapy was best studied in the setting of CMV retinitis with relapse in the pre-HAART era. In one study of 279 patients, the treatment protocol consisted of continuation of the previous therapy plus induction with the alternative drug (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ) for two weeks followed by standard maintenance doses of both ganciclovir (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and foscarnet (90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/38\">",
"     38",
"    </a>",
"    ]. Time to retinitis progression was significantly longer with the combination regimen.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has never been studied for gastrointestinal CMV disease and is associated with serious toxicity. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Cidofovir'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a result, we prefer the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    monotherapy or combined therapy and optimization of HAART for salvage. We recommend",
"    <strong>",
"     NOT",
"    </strong>",
"    using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    unless combination ganciclovir and foscarnet therapy have failed or the patient is intolerant of these medications due to significant toxicities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications used for the treatment of CMV disease have very different side effect profiles (",
"    <a class=\"graphic graphic_table graphicRef70634 \" href=\"UTD.htm?4/25/4509\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ganciclovir or valganciclovir",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia and thrombocytopenia have been the main toxicities of chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      therapy in patients with AIDS, and can be dose limiting [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22504/abstract/39\">",
"       39",
"      </a>",
"      ]. We recommend monitoring of the complete blood count a minimum of twice weekly during induction therapy. In patients who develop an absolute neutrophil count less than 500 cells, we recommend initiation of hematopoietic growth factors (G-CSF and GM-CSF). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link&amp;anchor=H6#H6\">",
"       \"Ganciclovir and valganciclovir: An overview\", section on 'Toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who develop severe thrombocytopenia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      should be discontinued and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      should be initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Foscarnet",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reversible increases in serum creatinine and electrolyte disturbances are common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , including symptomatic hypocalcemia during drug infusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"       \"Foscarnet: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum creatinine and electrolytes (calcium, magnesium, and phosphorus) should be monitored twice weekly during induction therapy. Intravenous hydration with normal saline should precede and continue during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      treatment. Administration of other nephrotoxic drugs should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      can cause serious, irreversible nephrotoxicity via proximal tubular cell injury. Saline hydration and high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      therapy (which can block cidofovir uptake by proximal renal tubular cells) have been given concomitantly with cidofovir in an attempt to reduce the risk of serious renal injury. Neutropenia, peripheral neuropathy, hypotony (abnormally low intraocular pressure), anterior uveitis, and alopecia also have been reported with cidofovir.",
"     </li>",
"     <li>",
"      In an attempt to prevent progressive renal injury, dipstick of the urine for protein (or measurement of the total protein-to-creatinine ratio in a random urine specimen) and the serum creatinine concentration should be performed immediately before each",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      dose. The drug should be discontinued if the dipstick is 2+ or more or serum creatinine rises by more than 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      over baseline. Other nephrotoxic drugs must be avoided when using cidofovir.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of active CMV disease is the result of reactivation of latent infection. End-organ disease probably results from the hematogenous spread of CMV. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Risk Factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for CMV disease include viremia and advanced immunosuppression, particularly when CD4+ T cell counts are less than 50",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical Manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMV disease can involve any part of the gastrointestinal tract; however the most common locations include the esophagus and colon. Patients with esophagitis present with odynophagia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysphagia; patients with colitis present with fever, weight loss, abdominal pain and diarrhea, which may be bloody. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of CMV is based on a triad of clinical symptoms, visualization of ulcers or erosions, with supportive pathology showing tissue destruction and viral inclusion bodies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of CMV antibody is not clinically useful except when the serology is negative. Caution should be exercised regarding the detection of CMV viremia, since viremia may be present in the absence of invasive disease.",
"     </li>",
"     <li>",
"      Patients with extraocular CMV disease often have concurrent CMV retinitis. As a result, any patient diagnosed with CMV gastrointestinal disease should begin formal ophthalmologic screening for retinitis, with examinations repeated at six-month intervals until the patient's absolute CD4 count has been restored to &gt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      by antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ophthalmologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Induction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      (90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily) for induction therapy of CMV gastrointestinal disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although both appear to be equally effective, we suggest first using ganciclovir because of the cost, inconvenience, and renal toxicity associated with foscarnet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who do not tolerate treatment with one drug can be switched to the other. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend induction therapy be continued for three to six weeks (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); duration is dependent on the rapidity of the patient's clinical response and tolerance of the medication.",
"     </li>",
"     <li>",
"      We suggest switching to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      (900 mg twice daily) to complete induction therapy once the presenting clinical manifestations have resolved (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend initiation of HAART when the patients presenting clinical symptoms have resolved (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (900 mg per day) in patients who have had a relapse of CMV gastrointestinal disease (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Reinduction therapy is required before maintenance therapy can begin. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Maintenance therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Salvage therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who fail to respond to anti-CMV therapy or who relapse despite chronic maintenance therapy, we recommend switching to the alternative agent that was not used initially (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      ) or use of combined therapy; both approaches should incorporate optimization of HAART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend NOT using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      unless combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      therapy have failed or the patient is intolerant of these medications (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twice-weekly monitoring of the complete blood count during induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      is indicated. Patients who develop an absolute neutrophil count less than 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      can be managed with colony stimulating growth factors. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Ganciclovir or valganciclovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twice-weekly monitoring of serum electrolytes (calcium, magnesium, and phosphorus) is indicated in patients who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , with electrolyte supplementation as needed during induction therapy. Twice-weekly monitoring of serum creatinine and IV hydration with 1 liter of saline during foscarnet infusions are also indicated. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Foscarnet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/1\">",
"      Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223.",
"     </a>",
"    </li>",
"    <li>",
"     Baril, L, Jouan, M, Caumes, E, et al. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients (abstract #I-31). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997; Toronto, Canada.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/3\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/4\">",
"      Shinkai M, Bozzette SA, Powderly W, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997; 175:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/5\">",
"      Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998; 158:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/6\">",
"      Chachoua A, Dieterich D, Krasinski K, et al. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med 1987; 107:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/7\">",
"      Mentec H, Leport C, Leport J, et al. Cytomegalovirus colitis in HIV-1-infected patients: a prospective research in 55 patients. AIDS 1994; 8:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/8\">",
"      Wilcox CM, Straub RF, Schwartz DA. Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. Am J Med 1995; 98:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/9\">",
"      Yust I, Fox Z, Burke M, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/10\">",
"      Wilcox CM, Straub RF, Schwartz DA. Prospective endoscopic characterization of cytomegalovirus esophagitis in AIDS. Gastrointest Endosc 1994; 40:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/11\">",
"      Vanegas F, Montalvo RD, Alvarez OA, et al. Massive upper gastrointestinal hemorrhage due to cytomegalovirus infection in two patients with acquired immunodeficiency syndrome. South Med J 2000; 93:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/12\">",
"      Chamberlain RS, Atkins S, Saini N, White JC. Ileal perforation caused by cytomegalovirus infection in a critically ill adult. J Clin Gastroenterol 2000; 30:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/13\">",
"      Wilcox CM, Schwartz DA. Symptomatic CMV duodenitis. An important clinical problem in AIDS. J Clin Gastroenterol 1992; 14:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/14\">",
"      Kyriazis AP, Mitra SK. Multiple cytomegalovirus-related intestinal perforations in patients with acquired immunodeficiency syndrome. Report of two cases and review of the literature. Arch Pathol Lab Med 1992; 116:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/15\">",
"      Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991; 4 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/16\">",
"      Orenstein JM, Dieterich DT. The histopathology of 103 consecutive colonoscopy biopsies from 82 symptomatic patients with acquired immunodeficiency syndrome: original and look-back diagnoses. Arch Pathol Lab Med 2001; 125:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/17\">",
"      Epstein JB, Sherlock CH, Wolber RA. Oral manifestations of cytomegalovirus infection. Oral Surg Oral Med Oral Pathol 1993; 75:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/18\">",
"      Wilcox CM, Chalasani N, Lazenby A, Schwartz DA. Cytomegalovirus colitis in acquired immunodeficiency syndrome: a clinical and endoscopic study. Gastrointest Endosc 1998; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/19\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/20\">",
"      Rene E, Marche C, Chevalier T, et al. Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. Dig Dis Sci 1988; 33:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/21\">",
"      Laine L, Bonacini M, Sattler F, et al. Cytomegalovirus and Candida esophagitis in patients with AIDS. J Acquir Immune Defic Syndr 1992; 5:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/22\">",
"      Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993; 119:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/23\">",
"      Frank D, Raicht RF. Intestinal perforation associated with cytomegalovirus infection in patients with acquired immune deficiency syndrome. Am J Gastroenterol 1984; 79:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/24\">",
"      Dieterich DT, Poles MA, Lew EA, et al. Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Antimicrob Agents Chemother 1997; 41:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/25\">",
"      Nelson MR, Connolly GM, Hawkins DA, Gazzard BG. Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. Am J Gastroenterol 1991; 86:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/26\">",
"      Dieterich DT, Kotler DP, Busch DF, et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 1993; 167:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/27\">",
"      Blanshard C, Benhamou Y, Dohin E, et al. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995; 172:622.",
"     </a>",
"    </li>",
"    <li>",
"     Benson, C, Kaplan, J, Masur, H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/29\">",
"      Blanshard C. Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. J Acquir Immune Defic Syndr 1992; 5 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/30\">",
"      Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/31\">",
"      Curran M, Noble S. Valganciclovir. Drugs 2001; 61:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/32\">",
"      Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/33\">",
"      Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/34\">",
"      Dieterich DT, Poles MA, Dicker M, et al. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. Am J Gastroenterol 1993; 88:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/35\">",
"      Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/36\">",
"      Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/37\">",
"      Salzberger B, Stoehr A, Heise W, et al. Foscarnet and ganciclovir combination therapy for CMV disease in HIV-infected patients. Infection 1994; 22:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/38\">",
"      Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996; 114:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22504/abstract/39\">",
"      Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6:515.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3751 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-84E1ECB1DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22504=[""].join("\n");
var outline_f21_62_22504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impact of HAART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Enteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ophthalmologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Initiation of HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ganciclovir or valganciclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Foscarnet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Risk Factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3751|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/6/33893\" title=\"picture 1\">",
"      CMV esophagitis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3751|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/41/24221\" title=\"table 1\">",
"      Drug monitoring CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4509\" title=\"table 2\">",
"      Complications Rx CMV retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7623?source=related_link\">",
"      AIDS-related cytomegalovirus neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=related_link\">",
"      Evaluation of abdominal pain in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22505="Secondhand smoke exposure: Effects in adults";
var content_f21_62_22505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondhand smoke exposure: Effects in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Jonathan M Samet, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22505/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/62/22505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few epidemics as devastating and preventable as that caused by tobacco consumption. Cigarette smoking and exposure to secondhand smoke (SHS) became highly prevalent in most developed countries through the 20th century; with a lag of several decades, the rise of smoking was followed by epidemic increases in the diseases now known to be caused by smoking, including lung and other cancers, coronary heart disease, and chronic lung disease. By mid-century, epidemiologic studies provided the initial evidence establishing that smoking caused these diseases. Mounting evidence and authoritative syntheses in the reports of the United States (US) Surgeon General soon led to definitive conclusions concerning smoking as a cause of disease. Unfortunately, as the 21st century begins, smoking is on the rise in developing countries, even as it declines in the developed countries that have had some success with tobacco control.",
"   </p>",
"   <p>",
"    This topic will focus on the health consequences of SHS in adults. Issues related to SHS exposure to a",
"    <span class=\"nowrap\">",
"     fetus/child",
"    </span>",
"    and effects of active cigarette smoking are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of SHS and health has a relatively brief history compared to active smoking, although the irritating nature of tobacco smoke to the nonsmoker has long been chronicled. Some of the first epidemiological studies on SHS and health were reported in the late 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]; there had been scattered case reports previously, and there were campaigns against smoking in public in Nazi Germany. One German physician, Fritz Lickint, used the term \"passive smoking\" in his 1939 book on smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/4\">",
"     4",
"    </a>",
"    ]. The 2006 Surgeon General's report uses the term \"secondhand smoke,\" although the term \"environmental tobacco smoke\" (ETS), originating within the tobacco industry, was used more frequently in earlier reports and discussions on the topic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial epidemiological investigations focused upon parental smoking and lower respiratory illnesses in infants; studies of lung function and respiratory symptoms in children soon followed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The first major studies on SHS smoke and lung cancer in nonsmokers were reported in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and by 1986 the evidence supported the conclusion that SHS was a cause of lung cancer in nonsmokers, a conclusion reached by the International Agency for Research on Cancer (IARC), the US Surgeon General, and the US National Research Council [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. Subsequently, a now substantial body of evidence has continued to identify new diseases and other adverse effects of SHS, including increased risk for coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/6,12-15\">",
"     6,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006 US Surgeon General's Report leaves no doubt that any exposure to tobacco smoke is harmful to human health [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/5\">",
"     5",
"    </a>",
"    ]. The findings on SHS and disease have been the foundation of the drive for smoke-free indoor environments and for educating parents concerning the effects of their smoking on their children's health. As bans are implemented, an increasing body of evidence documents reduction of exposure and benefits for cardiovascular and respiratory health.",
"   </p>",
"   <p>",
"    The tobacco industry's campaign to discredit the evidence on active smoking initially and on SHS subsequently is now well documented as legal actions against the tobacco industry have led to the release of millions of industry documents. A US Federal Court decision found the tobacco companies to be guilty of fraud and racketeering, citing their actions around SHS as one instance of such activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/16\">",
"     16",
"    </a>",
"    ]. The industry's actions were attributable to fear of the policy implications of the findings on SHS. The tactics used to discredit the scientific evidence on SHS included the use of consultant experts who raised endless concerns about the data, sometimes without revealing their employment by the tobacco industry; support for meetings and publications speaking to limitations of the evidence on SHS; and more subtle infiltration of scientific organizations and even public health organizations, including the World Health Organization. Readers of the scientific literature need to be aware that there was an attempt to maintain seeming controversy among scientists even as the evidence mounted and supported converging conclusions by expert panels on the adverse effects of SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/17\">",
"     17",
"    </a>",
"    ]. Industry websites now acknowledge the conclusions on SHS by public health authorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHAT IS SECONDHAND SMOKE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondhand smoke is one of several terms used for the smoke inhaled involuntarily by nonsmokers. The smoke inhaled by nonsmokers is often referred to as secondhand smoke (SHS) or environmental tobacco smoke (ETS). At present, 1.3 billion adults worldwide are smokers, implying that SHS exposure is almost unavoidable for children and for the two-thirds of adults who do not smoke.",
"   </p>",
"   <p>",
"    SHS is a mixture of sidestream (SS) smoke given off by the smoldering cigarette (or pipe or cigar) and of mainstream (MS) smoke that is exhaled back into the air by active smokers. Sidestream smoke, generated under the lower temperature conditions in the smoldering cigarette, has higher concentrations of many of the toxic compounds found in MS. However, it is quickly diluted as it moves away from the cigarette to contaminate the immediate environment. While there are quantitative differences between SHS and the MS inhaled by the active smoker, there is sufficient qualitative similarity to have warranted concern that the health of nonsmokers may be injured by SHS, just as active smokers are harmed by MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term &ldquo;thirdhand smoke&rdquo; has been used to refer to smoke components deposited on surfaces, along with metabolites of these components generated through oxidative chemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/18\">",
"     18",
"    </a>",
"    ]. There is potential public health impact through dermal or oral absorption of the smoke components and metabolites, which may be carcinogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measurement of secondhand smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In environments where smoking takes place, components of tobacco smoke can readily be measured in the air, including small particles in the size range that penetrates into the lung, carbon monoxide, nicotine, and benzene. Concentrations of the smoke components depend upon the number of smokers and their smoking patterns, the size of the space where smoking is taking place, the rate of exchange of the air of the space with outdoor air, and the presence and efficiency of air cleaning devices. The exposures of nonsmokers will also depend upon proximity to smokers, particularly during the time that they are actively smoking. A baby held by a smoking mother might be inhaling dense and virtually undiluted SS, while older children could leave a room if annoyed by the smoking of their parents.",
"   </p>",
"   <p>",
"    Measurements of several airborne components of SHS have been made in homes, workplaces, and public places to characterize the contribution of smoking to indoor air pollution. These studies have shown that cigarette smoking is a strong source of small particles in the air, the same size of particles that are regulated in outdoor air by the Environmental Protection Agency. Concentrations of particles in homes with smokers are typically at least double those of homes without smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nicotine, present as a gas in SHS, can be readily measured in indoor air using either active or passive samplers. Its presence is highly specific for tobacco smoke, as there are no other sources. Abundant nicotine measurements made over the last several decades confirm that SHS has been widely prevalent in the workplace and in homes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/20\">",
"     20",
"    </a>",
"    ]. A 31-country study showed that median air nicotine levels were 17-fold higher in homes where smoking takes place compared to those without smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The secondhand smoker also inhales other components of tobacco smoke. Benzene, which causes leukemia, is generated by tobacco combustion and may contribute to the increased risk of leukemia in active smokers compared with nonsmokers. Secondhand smoke is one of the major sources of benzene exposure for nonsmokers, making a contribution to exposure that rivals that from filling a car with gasoline and exceeding the contribution of petrochemical plants in nearby residences.",
"   </p>",
"   <p>",
"    Exposure to SHS can also be documented by the measurement of biomarkers, that is, tobacco smoke components or metabolites of these components in body fluids of nonsmokers, including blood, urine, saliva, and also in hair. Studies using biomarkers show clearly that SHS-exposed nonsmokers absorb, metabolize, and excrete tobacco smoke components, including nicotine and tobacco-specific carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/19\">",
"     19",
"    </a>",
"    ]. Although small amounts of nicotine may be ingested in certain foods, most of the nicotine and its metabolites detectable in body fluids reflect exposure to active or passive tobacco smoke. In the 31-country study of exposures of women and children to SHS at home, levels of hair nicotine in children living with smokers were about 2-fold higher compared to those not living with smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cotinine, the principal metabolite of nicotine, has been the most studied biomarker. Levels of cotinine in nonsmokers previously reached several percent of those in active smokers. In an analysis of blood from a national survey in the US during the late 1980s, cotinine could be detected in almost the entire sample using a very sensitive assay procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/19\">",
"     19",
"    </a>",
"    ]. There is strong evidence that SHS exposure is decreasing in the US, suggesting that these control strategies are having important effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In the 2002 data from the National Health and Human Nutrition Examination Survey, the proportion of US nonsmokers with cotinine concentrations of 0.05",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or greater fell by 43 percent in comparison with data from 1988-90 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/22\">",
"     22",
"    </a>",
"    ]. More recent data from the National Health and Nutrition Examination Survey (NHANES) in 2003 to 2004 show a further decrease of 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nonsmokers, tobacco-smoke carcinogens have also been shown to be bound to cellular DNA and albumin as adducts, and nonsmokers experimentally exposed to SHS excrete NNAL, a carcinogenic nitrosamine found in tobacco smoke, as do those exposed by living with smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/25\">",
"     25",
"    </a>",
"    ]. These observations, together with studies of biomarkers confirm the wide extent of SHS exposure and support the plausibility of adverse effects of SHS by demonstrating uptake of tobacco smoke components by exposed nonsmokers. The 2006 Surgeon General's report concludes that \"the evidence is sufficient to infer that exposure of nonsmokers to secondhand smoke causes &hellip; an increased risk for lung cancer\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEALTH CONSEQUENCES OF SECONDHAND SMOKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of the health risks of involuntary smoking comes from epidemiological studies, which have directly assessed the associations of measures of secondhand smoke (SHS) exposure with disease outcomes. Judgments about the causality between SHS exposure and health outcomes are also based upon extensive evidence derived from the biological and toxicological investigation of the health consequences of active smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The literature on SHS and health has been periodically reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7,11-14,26-28\">",
"     7,11-14,26-28",
"    </a>",
"    ]. One review was completed in 2005 by the California Environmental Protection Agency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/15\">",
"     15",
"    </a>",
"    ] and another review in 2006 by the office of the US Surgeon General [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/5\">",
"     5",
"    </a>",
"    ]. Causal conclusions were reached as early as 1986, when involuntary smoking was found to be a cause of lung cancer in nonsmokers by the International Agency for Research on Cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/10\">",
"     10",
"    </a>",
"    ], the US Surgeon General [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7\">",
"     7",
"    </a>",
"    ], and the US National Research Council [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/11\">",
"     11",
"    </a>",
"    ]. Each of these reports interpreted the available epidemiologic evidence in the context of the deep understanding of active smoking and lung cancer. In spite of somewhat differing approaches for reaching a conclusion, the findings of the three reports were identical: involuntary smoking is a cause of lung cancer in nonsmokers. This and subsequent causal conclusions have had broad public health impact. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1986, the reports of the US Surgeon General and the National Research Council also addressed the then-mounting evidence of adverse respiratory effects of SHS exposure for children. Subsequent reports, including the 2006 Surgeon General's report, identified further effects of SHS exposure on children, and the more recent reports have classified SHS as causing a number of adverse effects for exposed children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annoyance and irritation, although not representing an illness or disease, are also firmly linked to exposure to SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7,29\">",
"     7,29",
"    </a>",
"    ]. Surveys document discomfort involving the eye and upper airways; confirmatory evidence has been provided by studies involving exposures of volunteers to SHS in chambers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doses of carcinogens received from SHS exposure are far less than with active smoking. On the other hand, exposure to SHS can begin in childhood and extend across the full lifespan. SHS exposure is associated with an increased risk of lung cancer. One study estimated that exposure to SHS was responsible for 21,400 lung cancer deaths worldwide in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association between involuntary smoking and lung cancer is biologically plausible based upon the presence of carcinogens in sidestream smoke and the lack of a documented risk-free threshold dose for respiratory carcinogens in active smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/10,31\">",
"     10,31",
"    </a>",
"    ]. Furthermore, genotoxic activity, the ability to damage DNA, has been demonstrated for many components of SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. As mentioned above, experimental exposure of nonsmokers to SHS results in the urinary excretion of NNAL, a tobacco-specific carcinogen, and living with a smoker also leads to a higher level of NNAL in nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/35\">",
"     35",
"    </a>",
"    ]. Nonsmokers, including children, exposed to SHS also have increased concentrations of tobacco-related carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have shown that SHS is associated with lung cancer, and various review panels, including the 2006 US Surgeon General's report, have concluded that SHS exposure causes lung cancer in nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7-11,38-40\">",
"     7-11,38-40",
"    </a>",
"    ]. There appears to be a dose-response relationship between intensity of exposure and relative risk. Results of a meta-analysis including 52 studies prepared for the 2006 Surgeon General's report showed that the relative risk of lung cancer among male and female nonsmokers who were ever exposed to SHS from the spouse was 1.21 (95% CI 1.13-1.30). The magnitude of the effect was comparable for men and women, with no significant difference by geographic area [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40\">",
"     40",
"    </a>",
"    ]. A meta-analysis of 25 studies of lung cancer and exposure to SHS in the workplace prepared for the 2006 Surgeon General's report estimated a pooled relative risk of 1.22 (95% CI 1.13-1.33) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several studies showing increased risk of lung cancer from SHS in specific populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 24 studies found that, for men and women exposed during childhood to smoking by either parent, the odds ratio of lung cancer was 1.11 (95% CI 0.94-1.31) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40\">",
"       40",
"      </a>",
"      ]. For maternal exposure only, the odds ratio was 1.15 (95% CI 0.86-1.52), while for paternal exposure only, the odds ratio was 1.10 (95% CI 0.89-1.36).",
"     </li>",
"     <li>",
"      In a prospective cohort study of 91,540 nonsmoking women in Japan, standardized mortality ratios (SMRs) for lung cancer increased significantly with the amount smoked by the husbands [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/8\">",
"       8",
"      </a>",
"      ]. The findings could not be explained by confounding factors and were unchanged when follow-up of the study group was extended [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/38\">",
"       38",
"      </a>",
"      ]. There was also a significantly increased risk for nonsmoking men married to wives smoking one to 19 cigarettes and 20 or more cigarettes daily.",
"     </li>",
"     <li>",
"      In a population based, case-control study, household exposure to 25 or more smoker-years during childhood and adolescence doubled the risk of lung cancer, whereas exposure to fewer than 25 smoker-years did not increase the risk [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/41\">",
"       41",
"      </a>",
"      ]. It was estimated that 17 percent of lung cancer in nonsmokers is attributable to high levels of environmental smoke exposure during childhood and adolescence.",
"     </li>",
"     <li>",
"      In another similarly designed study, tobacco use by the spouse was associated with a 30 percent increase in risk of lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/42\">",
"       42",
"      </a>",
"      ]. The risk rose with increasing levels of pack-year exposure from the spouse; 80 or more pack-years of exposure was associated with an 80 percent excess risk of lung cancer.",
"     </li>",
"     <li>",
"      A meta-analysis of 37 published studies involving 4626 people with lung cancer found an excess risk of lung cancer of 24 percent (95% CI 13-36 percent) if an individual lived with a smoker [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/43\">",
"       43",
"      </a>",
"      ]. Adjustment for potential bias and confounding by diet did not alter the estimate. A significant dose-response relationship with the number of cigarettes smoked by the spouse and the duration of exposure was also documented. A more recent meta-analysis, involving 55 studies, found that women had a 27 percent increase in risk if married to a smoker [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cohort study subsequent to the above meta-analysis did not find an excess risk of lung cancer in spouses of smokers after 39 years of follow-up; however, the results of this study are weakened by its limited data on spousal smoking, which was only fully assessed at the start of the study without subsequent updating [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/45\">",
"       45",
"      </a>",
"      ]. Inclusion of this study in subsequent meta-analyses had little effect on the point estimate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/44,46\">",
"       44,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Panels reviewing these data have concluded that SHS causes cancer. In 1998, the United Kingdom's Scientific Committee on Tobacco and Health concluded that exposure to SHS is a cause of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/13\">",
"     13",
"    </a>",
"    ]. The US Environmental Protection Agency has classified SHS as a Group A carcinogen, that is, a known human carcinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/27\">",
"     27",
"    </a>",
"    ]. The International Agency for Research on Cancer (IARC) reached the same conclusion in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/47\">",
"     47",
"    </a>",
"    ], as did the 2006 Report of the Surgeon General [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for the development of lung cancer in response to SHS may be influenced by genetics. One study found a significant increase in polymorphisms in the gene glutathione S-transferase M1 (GSTM1) among 51 nonsmoking women with exposure to SHS who developed lung cancer compared with 55 nonsmoking women with lung cancer who had no environmental tobacco smoke exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/48\">",
"     48",
"    </a>",
"    ]. In another population-based study among never smokers, in those with high SHS exposure, GSTM1 and GSTP1 polymorphisms were associated with over a 4-fold increased risk of developing lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/49\">",
"     49",
"    </a>",
"    ]. GST is believed to play a role in detoxifying carcinogens in tobacco smoke; therefore, mutations which decrease its activity could serve to promote tumorigenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other respiratory tract illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cross-sectional studies have investigated the association between respiratory symptoms in adult nonsmokers and involuntary exposure to tobacco smoke. These studies have primarily considered exposure outside the home. Consistent evidence of an effect of passive smoking on chronic respiratory symptoms in adults has not been found [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/50-56\">",
"     50-56",
"    </a>",
"    ], although the small particles in SHS would be anticipated to reach the airways and alveoli and potentially cause injury. Several studies suggest that passive smoking may cause acute respiratory morbidity (ie, illnesses and symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/57-63\">",
"     57-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    People with asthma and chronic obstructive pulmonary disease (COPD) may be at increased risk from SHS exposure. However, experimental studies have not clearly demonstrated a role of SHS in exacerbating asthma in adults. The acute responses of asthmatics to SHS have been assessed by exposing persons with asthma to tobacco smoke in a chamber. This experimental approach cannot be readily controlled because of the impossibility of blinding subjects to exposure to SHS. However, suggestibility does not appear to underlie physiological responses of asthmatics of SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/64\">",
"     64",
"    </a>",
"    ]. Of three studies involving exposure of unselected asthmatics to SHS, only one showed a definite adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. One study recruited 21 asthmatics who reported exacerbation with exposure to SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/69\">",
"     69",
"    </a>",
"    ]. With challenge in an exposure chamber at concentrations much greater than typically encountered in indoor environments, seven of the subjects experienced a more than 20 percent decline in FEV1.",
"   </p>",
"   <p>",
"    Several studies have shown improvement in the status of people with asthma after the implementation of workplace bans on smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/63,70\">",
"     63,70",
"    </a>",
"    ]. In Scotland, following the national smoking ban in 2006, the respiratory health of asthmatic and nonasthmatic bar workers improved [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to SHS has been associated in cross-sectional investigations with reduction of several lung function measures. However, the findings have not been consistent and methodologic issues constrain interpretation of the findings. Thus, a conclusion cannot yet be reached on the effects of SHS exposure on lung function in adults.",
"   </p>",
"   <p>",
"    In a matched case-control study, SHS was associated with chronic rhinosinusitis, particularly at the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that exposure to SHS causes almost 40,000 deaths from heart disease each year in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/72\">",
"     72",
"    </a>",
"    ], reflecting the increased risk in nonsmokers of coronary disease and coronary death by approximately 20 percent in large epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The 2006 Surgeon General's report stated that pooled relative risks from meta-analyses indicate a 25 to 30 percent increase in the risk of coronary heart disease from exposure to SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40\">",
"     40",
"    </a>",
"    ]. Worldwide, it is estimated that exposure to SHS caused 379,000 deaths from ischemic heart disease in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies show that exposure to SHS in healthy young volunteers compromises coronary artery endothelial function in a manner that is indistinguishable from that of active smokers, suggesting that endothelial dysfunction may be an important mechanism by which SHS increases CHD risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/40,75\">",
"     40,75",
"    </a>",
"    ]. A cross-sectional study found that after controlling for some potential confounders, exposure to SHS was associated with increased inflammatory markers including higher white blood cell counts and levels of C-reactive protein, homocysteine, fibrinogen, and oxidized LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/76\">",
"     76",
"    </a>",
"    ]. Effects of active cigarette smoking are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the risk estimates for SHS and CHD outcomes vary, most studies show modest increases in risk. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study from the American Cancer Society CPS-II cohort of 309,599 married pairs and 135,237 individuals found that exposure to smoking from a wife among men who never smoked led to a 20 percent higher coronary death rate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/73\">",
"       73",
"      </a>",
"      ]. There was no significant increase in risk in nonsmoking wives of smoking husbands or in living with former smokers.",
"     </li>",
"     <li>",
"      Data from the Nurses' Health Study involving 32,046 subjects found a relationship between the amount of SHS exposure and the risk of CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/77\">",
"       77",
"      </a>",
"      ]. Compared to women not exposed to SHS, the relative risk of CHD, after adjustment for other cardiovascular risk factors, was 1.58 among women who reported occasional exposure and 1.91 among those reporting regular exposure.",
"     </li>",
"     <li>",
"      Meta-analyses of published studies involving smokers or nonsmokers living with smokers estimate that the relative risk of CHD associated with SHS is 1.25 to 1.30 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Moreover there was a dose-response relationship with a relative risk of 1.23 and 1.31 for nonsmokers exposed to 1 to 19 and &ge;20 cigarettes per day, respectively, as compared to nonsmokers not exposed to smoke [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One prospective cohort study examining the effects of SHS also measured serum cotinine concentrations to assess environmental exposure objectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/80\">",
"       80",
"      </a>",
"      ]. After 20 years of follow-up, among the 2105 men who were nonsmokers, the risk of CHD was increased in those with higher serum cotinine concentrations. Compared with men in the lowest quartile of serum cotinine concentration, the risks in the second, third, and fourth quartiles were 1.45, 1.49, and 1.57, respectively. No consistent association was found between serum cotinine concentration and stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before-after studies suggest that laws that limit public and workplace smoking may result in a rapid decrease in the risk of acute coronary syndrome (ACS) in both smokers and nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/81\">",
"     81",
"    </a>",
"    ]. One meta-analysis found that the rate of hospitalization for acute myocardial infarction decreased with time (0.83, 95% CI 0.80-0.87), following hospitalizations 12 months after implementation of smoking restriction laws [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/82\">",
"     82",
"    </a>",
"    ]. A review of the evidence by an Institute of Medicine Committee led to the conclusion that bans are causally linked to a reduction in ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SHS may also be associated with noncardiac vascular disease. A large cross-sectional study of 60,377 women in China found an association between stroke in women and smoking by their husbands [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/84\">",
"     84",
"    </a>",
"    ]. The prevalence of stroke increased with greater duration of smoking and with an increasing number of cigarettes smoked daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence suggests that active smoking may be a risk factor for diabetes, although the association between smoking and diabetes is not clearly causal (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H18#H18\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Smoking'",
"    </a>",
"    ). A 15-year cohort study also found an increased incidence of glucose intolerance in young adults ages 18 to 30 exposed to SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     All-cause mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few data on the association between all-cause mortality and SHS. One study estimated that exposure to SHS was responsible for more than 60,000 premature deaths worldwide in 2004, accounting for approximately 1 percent of total mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTROL OF SHS EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to SHS takes place in many different microenvironments. The contributions of different microenvironments to personal SHS exposures depend upon the time spent in those environments and the concentrations of SHS in the different locations. The contributions of different microenvironments also depend upon age, sex, and other sociodemographic factors. For children, the home is a dominant locus of exposure, while for adults the workplace and social environments may be significant loci.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) has offered policy recommendations to achieve smoke-free environments [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/86\">",
"     86",
"    </a>",
"    ]. Its Framework Convention for Tobacco Control calls for protection of nonsmokers against exposure to SHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/87\">",
"     87",
"    </a>",
"    ]. Although most countries have ratified the Framework Convention, only a small minority of the world population meet the recommended level of protection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/88\">",
"     88",
"    </a>",
"    ]. Control of SHS exposure in the home and elsewhere is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link\">",
"     \"Control of secondhand smoke exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESPONDING TO SPECIFIC CLINICAL QUESTIONS ABOUT SECONDHAND SMOKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondhand smoking remains highly prevalent and results in exposure to respiratory irritants and carcinogens. It has clinically relevant consequences, particularly for the health of children, and possibly for adults with chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease. From the public health perspective, passive smoking contributes to the population's risk for lung cancer and heart disease. It is a readily controllable form of environmental pollution that can be completely eliminated. A number of situations that may arise in clinical practice and suggested approaches are given below. There are now extensive resources available on the health effects of passive smoking that can be used by physicians working in public health and clinical domains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lung cancer and heart disease risk for adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the 1986 Report of the Surgeon General was released [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/7\">",
"     7",
"    </a>",
"    ], Dr. Everett Koop, the Surgeon General at the time, was asked if the causal conclusion with regard to lung cancer meant that nonsmokers should divorce smoking spouses. While divorce is a potential strategy to control exposure to SHS in the home, there are alternatives, as reviewed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link&amp;anchor=H9#H9\">",
"     \"Control of secondhand smoke exposure\", section on 'The home environment'",
"    </a>",
"    ). Lung cancer in never-smokers is not a rare disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/89\">",
"     89",
"    </a>",
"    ]; there are approximately 10,000 cases annually, of which approximately 2,000 to 3,000 are estimated to be attributable to SHS. Nonsmokers married to smokers have about a 20 percent greater risk for lung cancer and coronary heart disease than those married to nonsmokers. While this increment in risk is relatively modest, it can be readily reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Workplace exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adults in the US are now nonsmokers, and exposure to tobacco smoke in the workplace, if permitted, may be viewed as both an annoyance and a health risk. For the nonsmoker with asthma or perhaps chronic obstructive pulmonary disease, health care providers can reasonably postulate that the exposure may exacerbate respiratory illness. Fortunately, the majority of workers now report that their workplaces are smokefree in the US and in other developed countries.",
"   </p>",
"   <p>",
"    If asked about workplace risks from these exposures, health care providers can reasonably reply that the exposure would increase risk to some extent and that it could be reduced or eliminated with a workplace smoking policy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link&amp;anchor=H10#H10\">",
"     \"Control of secondhand smoke exposure\", section on 'Workplaces'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1491250\">",
"    <span class=\"h2\">",
"     Multi-unit housing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies show that people living in multi-unit housing may be exposed to SHS from smoking in other units [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22505/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. In some municipalities, smoking has been banned within apartment complexes or common areas of multi-unit housing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sick-building syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sick-building syndrome can be a complex clinical problem, requiring a clinical diagnosis in an individual to be based in a population context. Passive smoking should be considered as one of the factors that can contribute to the occurrence of sick-building syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER SOURCES OF INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thoracic Society (ATS) statement on cigarette smoking and health, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Reports of the Surgeon General of the US Public Health Service on the adverse health consequences of smoking and secondhand smoke (SHS) exposure can be found at",
"    <a class=\"external\" href=\"file://www.surgeongeneral.gov/library/reports/index.html\">",
"     www.surgeongeneral.gov/library/reports/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The US Centers for Disease Control and Prevention's Office of Smoking and Health (OSH) provides comprehensive information on the health effects of tobacco use and SHS exposure, data and statistics, and information on national and global tobacco control programs. The OSH resources are available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/tobacco/index.htm\">",
"     file://www.cdc.gov/tobacco/index.htm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The National Cancer Institute's fact sheets on smoking, as well as links to publications and other web resources can be accessed through",
"    <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/smoking\">",
"     www.cancer.gov/cancertopics/smoking",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       \"Patient information: Quitting smoking (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The smoke inhaled by nonsmokers is often referred to as secondhand smoke (SHS). At present, over one billion adults worldwide are smokers, implying that SHS exposure is a common risk for children and for adults who do not smoke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'What is secondhand smoke?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to SHS is causally associated with an increased risk of lung cancer and coronary heart disease among nonsmokers. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Health consequences of secondhand smoke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implementing laws that limit public and workplace smoking may result in a rapid decrease in the risk of acute myocardial infarction in both smokers and nonsmokers. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Workplace exposures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although SHS does not appear to be associated with chronic respiratory disease outside of lung cancer, several studies suggest that passive smoking may cause acute respiratory morbidity, particularly for people with asthma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other respiratory tract illness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/1\">",
"      Cameron P. The presence of pets and smoking as correlates of perceived disease. J Allergy 1967; 40:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/2\">",
"      Cameron P, Kostin JS, Zaks JM, et al. The health of smokers' and nonsmokers' children. J Allergy 1969; 43:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/3\">",
"      Colley JR, Holland WW. Social and environmental factors in respiratory disease. A preliminary report. Arch Environ Health 1967; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     Proctor RN. Cancer Wars. How Politics Shapes What We Know and Don't Know About Cancer, Basic Books, New York 1995.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services (USDHHS). The health effects of involuntary exposure to tobacco smoke. Centers for Disease Control and Prevention; Rockville, MD 2006.",
"    </li>",
"    <li>",
"     Samet JM, Wang SS. Environmental Tobacco Smoke. In: Environmental Toxicants: Human Exposures and Their Health Effects, Lippmann M (Ed), Van Nostrand Reinhold Company, Inc., New York 2000. p.319.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/7\">",
"      US Department of Health and Human Services (USDHHS). The health consequences of involuntary smoking: A report of the Surgeon General. 1986; DHHS Publication No. (CDC) 87-8398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/8\">",
"      Hirayama T. Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. Br Med J (Clin Res Ed) 1981; 282:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/9\">",
"      Trichopoulos D, Kalandidi A, Sparros L, MacMahon B. Lung cancer and passive smoking. Int J Cancer 1981; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Tobacco Smoking. 1986.",
"    </li>",
"    <li>",
"     National Research Council (NRC), Committee on Passive Smoking. Environmental tobacco smoke: Measuring exposures and assessing health effects. 1986.",
"    </li>",
"    <li>",
"     California Environmental Protection Agency (Cal EPA), Office of Environmental Health Hazard Assessment. Health Effects of Exposure to Environmental Tobacco Smoke. 1997.",
"    </li>",
"    <li>",
"     Scientific Committee on Tobacco and Health, HSMO. Report of the Scientific Committee on Tobacco and Health. 1998; 011322124x.",
"    </li>",
"    <li>",
"     World Health Organization. International Consultation on Environmental Tobacco Smoke (ETS) and Child Health: Consultation Report. 1999.",
"    </li>",
"    <li>",
"     Air Resources Board. Proposed identification of environmental tobacco smoke as a toxic air contaminant. California Environmental Protection Agency; Sacramento, CA 2005.",
"    </li>",
"    <li>",
"     Judge Gladys Kessler. United States of America vs. Philip Morris USA, Inc, etc. Civil Action No. 99-2496 (GK). 8-17-2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/17\">",
"      Tong EK, Glantz SA. Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease. Circulation 2007; 116:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/18\">",
"      Matt GE, Quintana PJ, Destaillats H, et al. Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect 2011; 119:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/19\">",
"      Coultas DB, Samet JM, McCarthy JF, Spengler JD. Variability of measures of exposure to environmental tobacco smoke in the home. Am Rev Respir Dis 1990; 142:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/20\">",
"      Hammond SK. Exposure of U.S. workers to environmental tobacco smoke. Environ Health Perspect 1999; 107 Suppl 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/21\">",
"      Wipfli H, Avila-Tang E, Navas-Acien A, et al. Secondhand smoke exposure among women and children: evidence from 31 countries. Am J Public Health 2008; 98:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/22\">",
"      Pirkle JL, Bernert JT, Caudill SP, et al. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988-2002. Environ Health Perspect 2006; 114:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/23\">",
"      Stranges S, Bonner MR, Fucci F, et al. Lifetime cumulative exposure to secondhand smoke and risk of myocardial infarction in never smokers: results from the Western New York health study, 1995-2001. Arch Intern Med 2006; 166:1961.",
"     </a>",
"    </li>",
"    <li>",
"     Public Use Data Tape, 2003-2004. National Center for Health Statistics; National Center for Health Statistics.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/25\">",
"      Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health Education and Welfare (DHEW). The health consequences of smoking. A report of the Surgeon General. DHEW Publication No. (HSM) 73-8704, 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/27\">",
"      US Environmental Protection Agency (EPA). Respiratory health effects of passive smoking: Lung cancer and other disorders. 1992; EPA/600/006F:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/28\">",
"      Eisner MD. Secondhand smoke at work. Curr Opin Allergy Clin Immunol 2010; 10:121.",
"     </a>",
"    </li>",
"    <li>",
"     Samet JM, Cain WS, Leaderer BP. Environmental tobacco smoke. In: Indoor Air Pollution: A health perspective, Samet JM, Spengler JD (Eds), 1991. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/30\">",
"      Oberg M, Jaakkola MS, Woodward A, et al. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2011; 377:139.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. health consequences of smoking: Cancer. A report of the Surgeon General. US Department of Health and Human Services, 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/32\">",
"      L&ouml;froth G. Environmental tobacco smoke: overview of chemical composition and genotoxic components. Mutat Res 1989; 222:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/33\">",
"      Claxton LD, Morin RS, Hughes TJ, Lewtas J. A genotoxic assessment of environmental tobacco smoke using bacterial bioassays. Mutat Res 1989; 222:81.",
"     </a>",
"    </li>",
"    <li>",
"     Weiss B. Behavior as an endpoint for inhaled toxicants. In: Concepts in inhalation toxicology, McClellan RO, Henderson RF (Eds), Hemisphere Publishing, New York 1989. p.475.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/35\">",
"      Hecht SS, Carmella SG, Murphy SE, et al. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993; 329:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/36\">",
"      Maclure M, Katz RB, Bryant MS, et al. Elevated blood levels of carcinogens in passive smokers. Am J Public Health 1989; 79:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/37\">",
"      Crawford FG, Mayer J, Santella RM, et al. Biomarkers of environmental tobacco smoke in preschool children and their mothers. J Natl Cancer Inst 1994; 86:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/38\">",
"      Hirayama T. Cancer mortality in nonsmoking women with smoking husbands based on a large-scale cohort study in Japan. Prev Med 1984; 13:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/39\">",
"      Trichopoulos D, Kalandidi A, Sparros L. Lung cancer and passive smoking: conclusion of Greek study. Lancet 1983; 2:677.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services (USDHHS). The health consequences of involuntary exposure to tobacco smoke. Centers for Disease Control and Prevention, Rockville, MD, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/41\">",
"      Janerich DT, Thompson WD, Varela LR, et al. Lung cancer and exposure to tobacco smoke in the household. N Engl J Med 1990; 323:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/42\">",
"      Fontham ET, Correa P, Reynolds P, et al. Environmental tobacco smoke and lung cancer in nonsmoking women. A multicenter study. JAMA 1994; 271:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/43\">",
"      Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/44\">",
"      Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007; 36:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/45\">",
"      Enstrom JE, Kabat GC. Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-98. BMJ 2003; 326:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/46\">",
"      Hackshaw A, International Agency for Research on Cancer. Passive smoking: paper does not diminish conclusion of previous reports. BMJ 2003; 327:501.",
"     </a>",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monograph 83: Tobacco smoke and involuntary smoking. Lyon, France 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/48\">",
"      Bennett WP, Alavanja MC, Blomeke B, et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 1999; 91:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/49\">",
"      Wenzlaff AS, Cote ML, Bock CH, et al. GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/50\">",
"      Kauffmann F, Dockery DW, Speizer FE, Ferris BG Jr. Respiratory symptoms and lung function in relation to passive smoking: a comparative study of American and French women. Int J Epidemiol 1989; 18:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/51\">",
"      Lebowitz MD, Burrows B. Respiratory symptoms related to smoking habits of family adults. Chest 1976; 69:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/52\">",
"      Schilling RS, Letai AD, Hui SL, et al. Lung function, respiratory disease, and smoking in families. Am J Epidemiol 1977; 106:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/53\">",
"      Comstock GW, Meyer MB, Helsing KJ, Tockman MS. Respiratory effects on household exposures to tobacco smoke and gas cooking. Am Rev Respir Dis 1981; 124:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/54\">",
"      Schenker MB, Samet JM, Speizer FE. Effect of cigarette tar content and smoking habits on respiratory symptoms in women. Am Rev Respir Dis 1982; 125:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/55\">",
"      Euler GL, Abbey DE, Magie AR, Hodgkin JE. Chronic obstructive pulmonary disease symptom effects of long-term cumulative exposure to ambient levels of total suspended particulates and sulfur dioxide in California Seventh-Day Adventist residents. Arch Environ Health 1987; 42:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/56\">",
"      Hole DJ, Gillis CR, Chopra C, Hawthorne VM. Passive smoking and cardiorespiratory health in a general population in the west of Scotland. BMJ 1989; 299:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/57\">",
"      Ostro BD. Estimating the risks of smoking, air pollution, and passive smoke on acute respiratory conditions. Risk Anal 1989; 9:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/58\">",
"      Schwartz J, Zeger S. Passive smoking, air pollution, and acute respiratory symptoms in a diary study of student nurses. Am Rev Respir Dis 1990; 141:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/59\">",
"      Leuenberger P, Schwartz J, Ackermann-Liebrich U, et al. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am J Respir Crit Care Med 1994; 150:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/60\">",
"      Robbins AS, Abbey DE, Lebowitz MD. Passive smoking and chronic respiratory disease symptoms in non-smoking adults. Int J Epidemiol 1993; 22:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/61\">",
"      Dayal HH, Khuder S, Sharrar R, Trieff N. Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ Res 1994; 65:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/62\">",
"      Riboli E, Slimani N, Kaaks R. Identifiability of food components for cancer chemoprevention. IARC Sci Publ 1996; :23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/63\">",
"      Eisner MD, Smith AK, Blanc PD. Bartenders' respiratory health after establishment of smoke-free bars and taverns. JAMA 1998; 280:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/64\">",
"      Urch RB, Silverman F, Corey P, et al. Does suggestibility modify acute reactions to passive cigarette smoke exposure? Environ Res 1988; 47:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/65\">",
"      Murray AB, Morrison BJ. The effect of cigarette smoke from the mother on bronchial responsiveness and severity of symptoms in children with asthma. J Allergy Clin Immunol 1986; 77:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/66\">",
"      Shephard RJ, Collins R, Silverman F. \"Passive\" exposure of asthmatic subjects to cigarette smoke. Environ Res 1979; 20:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/67\">",
"      Dahms TE, Bolin JF, Slavin RG. Passive smoking. Effects on bronchial asthma. Chest 1981; 80:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/68\">",
"      Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. J Allergy Clin Immunol 1981; 68:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/69\">",
"      Stankus RP, Menon PK, Rando RJ, et al. Cigarette smoke-sensitive asthma: challenge studies. J Allergy Clin Immunol 1988; 82:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/70\">",
"      Menzies D, Nair A, Williamson PA, et al. Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places. JAMA 2006; 296:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/71\">",
"      Tammemagi CM, Davis RM, Benninger MS, et al. Secondhand smoke as a potential cause of chronic rhinosinusitis: a case-control study. Arch Otolaryngol Head Neck Surg 2010; 136:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/72\">",
"      Glantz SA, Parmley WW. Passive smoking and heart disease. Mechanisms and risk. JAMA 1995; 273:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/73\">",
"      Steenland K, Thun M, Lally C, Heath C Jr. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation 1996; 94:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/74\">",
"      Wells AJ. Passive smoking as a cause of heart disease. J Am Coll Cardiol 1994; 24:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/75\">",
"      Otsuka R, Watanabe H, Hirata K, et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 2001; 286:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/76\">",
"      Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med 2004; 116:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/77\">",
"      Kawachi I, Colditz GA, Speizer FE, et al. A prospective study of passive smoking and coronary heart disease. Circulation 1997; 95:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/78\">",
"      Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ 1997; 315:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/79\">",
"      He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med 1999; 340:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/80\">",
"      Whincup PH, Gilg JA, Emberson JR, et al. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ 2004; 329:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/81\">",
"      Callinan JE, Clarke A, Doherty K, Kelleher C. Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2010; :CD005992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/82\">",
"      Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 2009; 120:1373.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand smoke exposure and cardiovascular effects: making sense of the evidence. National Academies Press; Institute of Medicine, Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/84\">",
"      Zhang X, Shu XO, Yang G, et al. Association of passive smoking by husbands with prevalence of stroke among Chinese women nonsmokers. Am J Epidemiol 2005; 161:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/85\">",
"      Houston TK, Person SD, Pletcher MJ, et al. Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study. BMJ 2006; 332:1064.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Protection from exposure to second-hand tobacco smoke. Policy recommendations. World Health Organization, Geneva 2007.",
"    </li>",
"    <li>",
"     World Health Organization. WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments. Geneva: World Health Organization, 2009.",
"    </li>",
"    <li>",
"     WHO report on global tobacco epidemic, 2011: warning about the dangers of tobacco. file://www.who.int/tobacco/en (Accessed on August 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/89\">",
"      Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5:e185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/90\">",
"      Kraev TA, Adamkiewicz G, Hammond SK, Spengler JD. Indoor concentrations of nicotine in low-income, multi-unit housing: associations with smoking behaviours and housing characteristics. Tob Control 2009; 18:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/91\">",
"      King BA, Travers MJ, Cummings KM, et al. Secondhand smoke transfer in multiunit housing. Nicotine Tob Res 2010; 12:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22505/abstract/92\">",
"      Wilson KM, Klein JD, Blumkin AK, et al. Tobacco-smoke exposure in children who live in multiunit housing. Pediatrics 2011; 127:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6919 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22505=[""].join("\n");
var outline_f21_62_22505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHAT IS SECONDHAND SMOKE?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measurement of secondhand smoke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEALTH CONSEQUENCES OF SECONDHAND SMOKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other respiratory tract illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      All-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTROL OF SHS EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESPONDING TO SPECIFIC CLINICAL QUESTIONS ABOUT SECONDHAND SMOKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lung cancer and heart disease risk for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Workplace exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1491250\">",
"      Multi-unit housing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sick-building syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER SOURCES OF INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=related_link\">",
"      Control of secondhand smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22506="Acute toxic-metabolic encephalopathy in children";
var content_f21_62_22506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute toxic-metabolic encephalopathy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Claudia A Chiriboga, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/62/22506/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/62/22506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxic-metabolic encephalopathy (TME) is a condition of acute global cerebral dysfunction resulting in altered consciousness, behavior changes, or seizures, which is not due to primary structural brain disease (eg, tumor or hemorrhage) or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. All forms of TME interfere with the function of the ascending reticular activating system",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its projections to the cerebral cortex, thus leading to impairment of arousal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    awareness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    TME usually is a consequence of systemic disorders and, therefore, the causes are diverse. The presentation of this condition in the newborn, infant, or child may be subtle and not easily recognized. Because TME often is reversible and interruption of neuronal activity in the developing brain can have a long-lasting effect, prompt recognition and treatment are important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal neuronal activity requires a balanced environment of electrolytes, water, amino acids, excitatory and inhibitory neurotransmitters, and metabolic substrates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, normal blood flow, normal temperature, normal osmolality, and physiologic pH are required for optimal brain function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/2\">",
"     2",
"    </a>",
"    ]. Complex systems, such as those mediating arousal and awareness, and those involved in higher cognitive functions, are more likely to malfunction when the local milieu is deranged [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of acute toxic-metabolic encephalopathy (TME) usually is multifactorial and varies according to etiology. TME generally results from cytotoxic injury or disruption of neurotransmission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Causes of cytotoxic injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disruption of energy production by inadequate cerebral blood flow, or lack of oxygen or glucose.",
"     </li>",
"     <li>",
"      Neuronal injury caused by exogenous drugs or toxins, or endogenous toxins that result from inadequate removal of wastes by the liver or kidney or an inborn error of metabolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"       \"Inborn errors of metabolism: Classification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebral edema or increased intracranial pressure (ICP), which may further compromise cerebral blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neuronal injury caused by autoantibodies directed against synaptic proteins or intracellular antigens, disorders that are sometimes associated with neoplasms. (See",
"      <a class=\"local\" href=\"#H8032025\">",
"       'Autoimmune or paraneoplastic encephalitis'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interference with neural transmission can result from electrolyte disturbances that affect the electrical properties of cellular membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Endogenous or exogenous toxins or drugs also can disrupt membrane polarization or interfere with neuronal activity by affecting neurotransmitters.",
"   </p>",
"   <p>",
"    In some disorders, a disturbed blood-brain barrier leads to the accumulation of systemic toxins as well as normal plasma constituents in the brain or cerebrospinal fluid (CSF) that interfere with neuronal function. Increased permeability of the blood-brain barrier is evidenced by elevated protein in the CSF, a frequent finding in TME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite a wide array of pathophysiologic mechanisms, the clinical manifestations of TME tend to be very similar because of a common final mechanism: interruption of polysynaptic pathways and altered excitatory-inhibitory amino acid balance and cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical features of acute toxic-metabolic encephalopathy (TME) are nonspecific and do not reliably identify a particular etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings in TME can range from subtle cognitive difficulties to florid delirium (a state of confusion with superimposed hyperactivity of the sympathetic limb of the autonomic nervous system with consequent tremor, tachycardia, diaphoresis, and mydriasis) or coma. The initial presentation may be subtle and include shortened attention span, disturbed cognitive function, and personality changes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Cognitive dysfunction may include impaired memory, perceptual deficits, and difficulty processing new information. Worsening brain dysfunction results in progressive disturbance of the level of consciousness from lethargy to obtundation, stupor, and coma.",
"   </p>",
"   <p>",
"    Fluctuations in mental status may occur, and manifestations can vary among individuals. Periods of hyper-alertness and drowsiness can alternate in some patients, with progressive increases in the duration of unresponsiveness. Others may appear alert, but become agitated and disoriented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Motor examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of motor abnormalities may be observed in patients with TME. Many of them have abnormal tone; persistent hypotonia or hypertonia can be seen. These abnormalities typically are diffuse and symmetric.",
"   </p>",
"   <p>",
"    Generalized or focal seizure activity occurs commonly. Abnormal movements, including myoclonic jerks, fine tremors, and asterixis (difficulty with postural maintenance, often seen as a coarse, flapping tremor of the hands), may occur. Primitive reflexes, such as suck or grasp responses, may be elicited on examination. Other common features include brisk deep tendon reflexes and extensor plantar responses. In severely obtunded subjects, decorticate and decerebrate posturing may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. Subtle movements generated by brainstem activity (including nystagmus, posturing, or sucking movements) may be seen in neonatal seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pupillary response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pupillary response may be helpful in identifying the etiology of TME. In an obtunded patient, the isolated lack of a pupillary response to light suggests ingestion of glutethimide or an anticholinergic drug. However, when coupled to coma and loss of other brainstem functions (eg, dolls eyes, corneal reflex) the finding suggests severe",
"    <span class=\"nowrap\">",
"     anoxic/ischemic",
"    </span>",
"    damage from hypoxic-ischemic encephalopathy (HIE) or intracranial pressure (ICP). In contrast, the pupillary response is typically, although not invariably, preserved if the etiology of obtundation or coma is non-structural (ie, the result of central nervous system depression such as seen with drug intoxication or liver failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Respiratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory abnormalities occur commonly in patients with TME. Hyperventilation caused by metabolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory acidosis or hypoventilation causing respiratory acidosis or caused by metabolic alkalosis can result from a variety of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxic-metabolic encephalopathy (TME) is a diagnosis of exclusion within a broad differential diagnosis. Important considerations in the differential diagnosis include sepsis, meningitis, brain tumor, and intracranial hemorrhage, including shaken baby syndrome. (See",
"    <a class=\"local\" href=\"#H30974781\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The history may help establish a possible etiology. Relevant information includes signs or symptoms of systemic illness, duration and progression of the encephalopathy, and possible exposure to medications or toxins. The family history may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory investigation of TME includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Blood glucose, electrolyte panel, and serum concentrations of blood urea nitrogen (BUN), creatinine, calcium, magnesium, and phosphate",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT], coagulation studies, and serum concentrations of bilirubin and ammonia)",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Rapid test for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and salicylates, in addition to a toxicology screen on blood and urine, and blood lead level",
"     </li>",
"     <li>",
"      Cultures of blood and cerebrospinal fluid (CSF)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Autoimmune/paraneoplastic",
"      </span>",
"      panel in blood (ie, antibodies to N-methyl-D-aspartate [NMDA] receptors and voltage-gated potassium channel antibodies [VGKC Ab]) and CSF (NMDA). (See",
"      <a class=\"local\" href=\"#H8032025\">",
"       'Autoimmune or paraneoplastic encephalitis'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When performing a lumbar puncture, it is important to measure the opening pressure to evaluate for Reye or Reye-like syndrome, in which intracranial pressure is high. Thyroid function tests and serum cortisol concentrations should be assessed if there are signs or symptoms suggesting an endocrinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the clinical findings, blood and urine should be tested for inborn errors of metabolism. If the patient is a newborn, the results of metabolic screening studies should be reviewed and may need to be repeated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography or magnetic resonance imaging (MRI) of the head should be performed to exclude structural causes of encephalopathy or head injury. Cranial ultrasonography can be used to perform rapid and portable screening in newborns (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    ). If shaken baby syndrome is considered, a radiographic skeletal survey should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/12\">",
"     12",
"    </a>",
"    ]. MRI is needed to assess demyelination or ischemia and patency of blood flow in cerebral sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electroencephalogram (EEG) can both confirm global cerebral dysfunction and exclude subclinical seizures with greater sensitivity than can clinical examination alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/4,6,11,13,14\">",
"     4,6,11,13,14",
"    </a>",
"    ]. In patients with overt seizures, the EEG will document epileptiform activity and characterize background activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30974781\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first goal of the laboratory and imaging studies described above are to exclude the following disorders, which can mimic acute toxic-metabolic encephalopathy (TME):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial hemorrhage &ndash; eg, due to accidental or abusive head trauma (&ldquo;shaken baby syndrome&rdquo;) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/12\">",
"       12",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sagittal sinus thrombosis &ndash; due to procoagulant states or dehydration; this can lead to severe increase in intracranial pressure and altered mentation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"       \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection &ndash; Meningitis or sepsis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mass effect &ndash; eg, due to brain tumor or hydrocephalus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link\">",
"       \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"       \"Hydrocephalus\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of acute toxic-metabolic encephalopathy (TME) depends upon the extent of encephalopathy. In any patient, all drugs with potential toxicity to the central nervous system should be discontinued, if possible. Patients with severe encephalopathy should be admitted to the intensive care unit (ICU). Regardless of the cause, many general measures should be instituted. As soon as an etiology is identified, specific treatment should be applied.",
"   </p>",
"   <p>",
"    General measures include monitoring and supportive care. In the acute stage, vital signs, including heart rate and blood pressure, are monitored continuously. Measurements of blood gas should be obtained to monitor ventilatory status, and metabolic status, especially glucose and electrolyte concentrations, should be assessed serially. Input and output should be measured. Severely obtunded patients may require placement of an intracranial pressure (ICP) monitor for direct measurement of ICP; this tool is essential in guiding the treatment of increased ICP in patients with Reye syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=see_link\">",
"     \"Treatment and prognosis of coma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive measures include provision of parenteral fluids and pressors as needed to support the systemic circulation and assisted ventilation, if needed. Maintenance of an appropriate systemic blood pressure is important to achieve adequate cerebral perfusion pressure. Increased ICP should be treated, and seizures that are diagnosed by electroencephalogram (EEG) should be controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H20#H20\">",
"     \"Elevated intracranial pressure in children\", section on 'Management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIFIC ETIOLOGIES OF ENCEPHALOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxic-metabolic encephalopathy (TME) can be caused by a variety of clinical disorders. The most common diagnoses vary according to age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypoxic-ischemic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxic-ischemic encephalopathy often is a straightforward diagnosis after an obvious precipitating event such as choking, drowning, or airway obstruction. Hypoxic-ischemic events that occur antepartum, intrapartum, or postnatally are a common cause of encephalopathy in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of hypoxic-ischemic encephalopathy include severe hypotension caused by massive hemorrhage or cardiac arrhythmias, or hypoxemia caused by carbon monoxide poisoning. The duration and severity of hypoxia or hypotension and the patient's preexisting neurologic status determine the magnitude of the neurologic insult [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common metabolic disorders that can result in encephalopathy are hypoglycemia and diabetic ketoacidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is a serious, reversible cause of encephalopathy. The most common cause is ketotic hypoglycemia, which typically occurs after a mild infectious illness in thin, undernourished young children, and leads to vomiting, encephalopathy, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes of hypoglycemia include excessive insulin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/18\">",
"     18",
"    </a>",
"    ], hepatitis, ethanol ingestion, and inborn errors of metabolism, such as glycogen storage disorders, defects in gluconeogenesis, and fatty acid oxidation defects. Other less common etiologies are endocrinopathies (eg, growth hormone or cortisol deficiency), Reye syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/19\">",
"     19",
"    </a>",
"    ], and insulin-secreting pancreatic tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"     \"Etiology of hypoglycemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of hypoglycemia are varied. Neurologic signs can range from confusion or delirium to coma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Focal or generalized seizures can occur, and focal deficits may suggest a stroke. Signs of increased epinephrine release (eg, tremor, diaphoresis) may occur but are not universal. Because hypoglycemia has such a wide range of manifestations, glucose concentration should be measured in any patient with acute neurologic dysfunction. Prompt treatment of low glucose levels with intravenous glucose generally will reverse the neurologic signs, although prolonged or recurrent episodes may result in persistent deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diabetic ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe diabetes mellitus who administer inadequate insulin or have an acute infection may develop diabetic ketoacidosis (DKA) with associated encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/20\">",
"     20",
"    </a>",
"    ]. Affected children typically have nausea, vomiting, abdominal pain, hyperventilation (to compensate for the metabolic acidosis), and altered levels of consciousness ranging from lethargy to coma. Treatment includes volume repletion and insulin administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of DKA may precipitate serious complications. Rapid reduction of serum osmolality may result in cerebral edema, a life-threatening condition that should be suspected when patients recovering from DKA develop headache or encephalopathy. Infants and children younger than five years of age and patients with new onset of diabetes mellitus appear to be most at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/21\">",
"     21",
"    </a>",
"    ]. DKA is most common in children with type 1 diabetes mellitus, but occasionally occurs in association with type 2 diabetes mellitus or other conditions associated with shifts in osmolar balance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"     \"Cerebral edema in children with diabetic ketoacidosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Hypernatremia'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19643240\">",
"    <span class=\"h3\">",
"     Inborn errors of metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy can be a prominent feature of many inborn errors of metabolism that present in the newborn period. In addition, some disorders result in recurrent episodes of encephalopathic changes associated with vomiting and hypotonia that may be associated with an intercurrent illness or prolonged fasting. Laboratory abnormalities at presentation include hypoglycemia, hyperammonemia, or lactic acidosis, depending on the type of inborn error of metabolism (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid and electrolyte disturbances are common causes of acute encephalopathy. Serum osmolality &gt;330",
"    <span class=\"nowrap\">",
"     mOsmol/kg",
"    </span>",
"    or &lt;260",
"    <span class=\"nowrap\">",
"     mOsmol/kg",
"    </span>",
"    may result in alterations in the level of consciousness, primarily if they occur acutely [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is defined as a serum sodium concentration &gt;145",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"     23",
"    </a>",
"    ]. Severe water depletion caused by diarrhea is the most common cause of acute hypernatremia encountered in emergency departments [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"     23",
"    </a>",
"    ]. Other causes include diabetes insipidus and excessive sodium administration. Hypernatremic dehydration that presents in the first few weeks after birth has been associated with unsuccessful breast feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Encephalopathy associated with hypernatremia can result from the condition itself or as a complication of its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Acutely, osmotic water loss from brain cells causes brain shrinkage that predisposes to focal bleeding, thrombosis, and infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. In response to initial shrinkage, the brain adapts by taking up and producing solutes that promote osmotic water movement back into the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Thus, neurologic symptoms are less likely to occur once the hypernatremia has been present for more than a few days. At this time, rapid correction of the hypernatremia (generally defined as more than 0.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    per hour) may result in cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with symptomatic hypernatremia typically present with hyperpnea, restlessness, a high-pitched cry, lethargy, and muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/26\">",
"     26",
"    </a>",
"    ]. In patients with hypernatremia, rehydration should be performed cautiously. Rapid rehydration with hypotonic fluids may result in cerebral edema or even pontine or extrapontine myelinolysis, leading to seizures or coma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H94208716#H94208716\">",
"     \"Treatment of hypovolemia (dehydration) in children\", section on 'Hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia generally is defined as a serum sodium concentration less than 137",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    The most common causes of hyponatremia encountered in the emergency department are gastrointestinal losses associated with vomiting or diarrhea (which lead sequentially to volume depletion, increased release of antidiuretic hormone, and retention of ingested water) and water intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"     23",
"    </a>",
"    ]. Hyponatremia also may be caused by water retention in patients with congestive heart failure or hepatic cirrhosis. Hyponatremia also occurs commonly after cerebral insults or neurosurgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/32\">",
"     32",
"    </a>",
"    ]. In these cases, the condition typically results from the syndrome of inappropriate antidiuretic hormone secretion (SIADH), cerebral salt wasting, or treatment of diabetes insipidus (a form of SIADH since exogenous hormone replacement is given). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Water movement into and out of the brain in hyponatremia occurs in the opposite direction from those in hypernatremia. Acutely, osmotic water entry from brain cells causes cerebral edema that is largely responsible for the associated neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. In response to initial brain swelling, the brain adapts by losing solutes, thereby leading to osmotic water movement out of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]. Thus, neurologic symptoms are less likely to occur once the hyponatremia has been present for more than a few days. At this time, overly rapid correction of the hyponatremia (generally defined as more than 10 to 12",
"    <span class=\"nowrap\">",
"     mEq/day)",
"    </span>",
"    may result in cerebral shrinkage and a type of neurologic injury called osmotic demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with symptomatic hyponatremia may present with lethargy, disorientation, or agitation, and may complain of nausea, anorexia, and muscle cramps [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"     23",
"    </a>",
"    ]. With advancing hyponatremia, the level of consciousness declines. Patients may develop Cheyne-Stokes respiration and generalized tonic-clonic seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy also can result from abnormalities in the serum levels of calcium or magnesium.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypocalcemia is defined as a serum calcium concentration &lt;9.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.25",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after the newborn period, and usually results from decreased secretion of parathyroid hormone (PTH) or, less often, resistance to either PTH or calcitriol (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link\">",
"       \"Etiology of hypocalcemia in infants and children\"",
"      </a>",
"      ). The clinical signs of hypocalcemia result from increased neuromuscular irritability. They include nonspecific signs, such as vomiting, irritability, and muscle weakness, and characteristic signs, such as tetany and positive Trousseau and Chvostek signs [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Laryngospasm and seizures can develop.",
"     </li>",
"     <li>",
"      Hypercalcemia is defined as a serum calcium concentration &gt;11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.75",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Serum calcium concentrations &gt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.75",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      can be life-threatening [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/34\">",
"       34",
"      </a>",
"      ]. Most cases of this disorder result from increased gastrointestinal absorption of calcium (eg, vitamin D intoxication) or increased calcium resorption from bone (eg, prolonged immobilization) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Clinical features of hypercalcemia include signs and symptoms related to the gastrointestinal tract (eg, anorexia, nausea, vomiting, and constipation), cardiovascular system (eg, hypertension, bradycardia), kidneys (eg, polydipsia, polyuria, nephrocalcinosis), and skin (eg, pruritus) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Neurologic manifestations include headache, irritability, weakness, and lethargy that may progress to behavioral changes, seizures, and coma.",
"     </li>",
"     <li>",
"      Hypomagnesemia is defined as a serum magnesium level &lt;1.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (0.75",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and results from excessive gastrointestinal or renal losses in most affected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Rarely, hypomagnesemia is congenital, caused by a genetic mutation in one of several genes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link&amp;anchor=H23#H23\">",
"       \"Etiology of hypocalcemia in infants and children\", section on 'Hypomagnesemia'",
"      </a>",
"      ). The signs and symptoms of this disorder are similar to those of hypocalcemia and result from increased neuromuscular irritability. Patients may present with confusion, irritability, or hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"       1",
"      </a>",
"      ]. Choreiform movements, nystagmus, coma, and generalized seizures may occur in severe cases [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Tremors, muscle twitching, and myoclonic jerks often are seen on examination. As with hypocalcemia, carpopedal spasm and positive Trousseau and Chvostek signs may be present.",
"     </li>",
"     <li>",
"      Hypermagnesemia is defined as a serum magnesium level &gt;2.2",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and is usually due to accidental overdose of magnesium-containing medications (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34403?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      , Epsom salts [",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      ], or magnesium-containing enemas), especially in patients with renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/23\">",
"       23",
"      </a>",
"      ]. Excessive levels result in lethargy, coma, and respiratory depression. Cardiovascular effects include hypotension and electrocardiographic changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Organ failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy may occur with hepatic or renal failure. It also may be associated with severe hypertension and acute pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hepatic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic failure may be acute or chronic, and etiology varies with the age of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/35\">",
"     35",
"    </a>",
"    ]. Causes of acute failure include viral hepatitis, ingestion of hepatotoxic substances, inborn errors of metabolism, autoimmune hepatitis, and Reye syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Drugs that can result in liver failure include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    , sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/22/34151?source=see_link\">",
"     pimozide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/36\">",
"     36",
"    </a>",
"    ]. Causes of chronic hepatic failure include Wilson disease, biliary atresia, and chronic heart failure. In these conditions, excessive protein intake, gastrointestinal bleeding, or intercurrent infection can precipitate hepatic encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link\">",
"     \"Acute liver failure in children: Etiology and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of hepatic encephalopathy is uncertain. It may reflect a reversible metabolic encephalopathy, brain atrophy, brain edema, or any combination of these conditions. In advanced coma, the effects of brain swelling, impaired cerebral perfusion, and reversible impairment of neurotransmitter systems cannot be distinguished. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial symptoms of hepatic encephalopathy include confusion, apathy, or lethargy, which may progress to decerebrate or decorticate posturing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Hallucinations and agitation may occur. Many patients develop asterixis. Other motor disturbances include grimacing and jerking and seizure activity. The prognosis of this condition is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Uremic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic encephalopathy can occur as a complication of advanced acute or chronic renal failure. The specific cause of this disorder is uncertain. The severity of neurologic abnormalities may not correlate with the level of azotemia, suggesting that the encephalopathy does not depend exclusively upon the serum concentration of urea. Creatinine, guanidines, parathormone, and defective oxygen use are responsible for some of the neurologic symptoms, including peripheral neuropathies.",
"   </p>",
"   <p>",
"    Early clinical features of uremic encephalopathy include lethargy, irritability, disorientation, hallucinations, and rambling speech [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/38\">",
"     38",
"    </a>",
"    ]. Coma occasionally occurs in acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Most uremic patients have mild diffuse weakness or peripheral neuropathy and show unsteadiness in their movements [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/5\">",
"     5",
"    </a>",
"    ]. Tremor, myoclonus, and asterixis (\"uremic flap\") are common occurrences and tend to vary in parallel with mental status. Tetany may be present, and focal or generalized seizures may occur. Clinical signs typically are reversed by hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Uremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Encephalopathy also can occur during or immediately after dialysis as a component of dialysis disequilibrium syndrome. This disorder is thought to be caused primarily by cerebral edema resulting from overly rapid removal of urea during hemodialysis. Early findings of this disorder include headache, nausea, disorientation, restlessness, blurred vision, and asterixis. More severely affected patients progress to confusion, seizures, coma, and even death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Intoxications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy resulting from the toxic effect of medication is an important diagnostic consideration in a patient with altered mental status or seizures. This condition can result from therapeutic overdose, unintentional ingestion, or deliberate abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. Drugs that result in altered levels of consciousness when present in high concentration include sedatives, anticholinergic agents, and salicylates (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 2",
"    </a>",
"    ). Chemotherapy may result in similar states regardless of drug level [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/39\">",
"     39",
"    </a>",
"    ], and is often associated with signs of acute leukoencephalopathy on brain magnetic resonance imaging (MRI) (high signal on T2 and fluid attenuated inversion recovery [FLAIR]) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/40\">",
"     40",
"    </a>",
"    ] and even changes in diffusion-weighted imaging (DWI), due to cytotoxic edema, especially with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Sedatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdosage of sedatives, such as benzodiazepines, barbiturates, glutethimide, and alcohol can cause ataxia, nystagmus, and dysarthria. Excessive serum concentrations of these medications result in hypotension, respiratory depression, flaccid paralysis with areflexia, and coma. In these cases, except for glutethimide, pupillary light reflexes are intact. In contrast, glutethimide ingestion typically results in midposition or moderately dilated pupils that may be unequal and do not respond to light. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anticholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic levels of anticholinergic agents (eg, tricyclic antidepressants, antipsychotic medication, benzodiazepines) can result in central nervous system (CNS) excitation, which may lead to confusion, delirium, hallucinations, and seizures. Some patients develop hyperpyrexia, cardiac arrhythmias, coma, and neuroleptic malignant syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Salicylates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate intoxication can produce encephalopathy manifested as lethargy, seizures, and coma, accompanied by respiratory depression and cardiovascular collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/43\">",
"     43",
"    </a>",
"    ]. These signs typically are preceded by hyperpnea, vomiting, restlessness, and delirium. Reye syndrome also is associated with salicylate ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H28202936\">",
"     'Reye syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19642442\">",
"    <span class=\"h3\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of immunosuppressive agents occasionally cause encephalopathy. Corticosteroids may cause insomnia, irritability, impaired concentration, and mood changes, including a florid steroid psychosis.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    can cause somnolence, headache, dysarthria, depression, and visual hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK 506) also may cause an encephalopathy characterized by anxiety, tremor, vivid nightmares, and restlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/46\">",
"     46",
"    </a>",
"    ]. As with chemotherapeutic agents, a leukoencephalopathy can be transiently observed on MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H20#H20\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Neurotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'CNS preventive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Environmental toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of environmental toxins can result in encephalopathy. Common agents include organophosphates, lead or other heavy metals, and hydrocarbons. Acute symptoms of organophosphate toxicity include headache, irritability, sweating, and twitching resulting in muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"     \"Organophosphate and carbamate poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lead ingestion may result in irritability, lethargy, and delayed cognitive and motor development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/48\">",
"     48",
"    </a>",
"    ]. Severely affected patients may present with seizures or coma, resulting from cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H15#H15\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Parainfectious encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute encephalopathy may be associated with a systemic illness. In these cases, encephalopathic changes may result either from direct viral invasion of the CNS or an indirect, immune-mediated response to the infectious agent.",
"   </p>",
"   <p>",
"    Postinfectious encephalomyelitis, also known as acute disseminated encephalomyelitis (ADEM), is an example of the latter mechanism. This disorder is briefly reviewed here, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ADEM occurs after infection by viruses, including measles, varicella, and rubella, or after some immunizations. It is thought to be caused by sensitized lymphocytes attacking the myelin sheath, resulting in demyelination.",
"   </p>",
"   <p>",
"    A febrile illness occurs in 50 to 75 percent of children with ADEM in the four weeks prior to the onset of typical neurologic symptoms, which typically appear 4 to 13 days after the infection or vaccination. Fever, headache, vomiting, and meningismus are often present at the time of initial presentation. Encephalopathy is a characteristic feature and usually develops rapidly in association with multifocal neurologic deficits. Progression of neurologic signs to maximum deficits usually occurs over four to seven days. The level of consciousness ranges from lethargy to frank coma.",
"   </p>",
"   <p>",
"    In addition to encephalopathy, the most common neurologic features of ADEM include long tract (pyramidal) signs, acute hemiparesis, cerebellar ataxia, cranial neuropathies including optic neuritis and seizures, and spinal cord dysfunction (transverse myelitis). Aphasia, movement disorders, and sensory deficits are less common.",
"   </p>",
"   <p>",
"    Most children with ADEM make a full recovery, usually slowly over four to six weeks. Approximately 60 to 90 percent have no neurologic deficits, while a range of neurologic sequelae are found in the remainder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When parainfectious encephalopathy develops in children younger than two years of age, the clinical and pathologic features are different from those in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/1\">",
"     1",
"    </a>",
"    ]. The relationship between this disorder and ADEM is uncertain. Generalized seizures and increased intracranial pressure (ICP) occur more commonly in the younger patients. Neuropathologic changes include cerebral edema and acute neuronal vacuolization and degeneration, rather than focal demyelination. The cause of this condition is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8032025\">",
"    <span class=\"h2\">",
"     Autoimmune or paraneoplastic encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A heterogeneous group of neurologic disorders are mediated by autoantibodies (autoimmune channelopathies). Symptoms suggestive of autoimmune encephalopathy, especially when they occur suddenly and de novo are: refractory seizure disorder, status epilepticus, delirium, movement disorder, or atypical psychiatric presentations (eg, hallucinations with delirium or seizures; profound insomnia). In adults, autoimmune encephalopathies are usually associated with neoplasms, are considered paraneoplastic syndromes, and are mediated by a variety of antibodies to intracellular antigens or synaptic proteins. Of described antibodies, a few are not seen in children (eg, AMPA receptor encephalitis). The most frequent cause of autoimmune encephalopathy in children is N-methyl-D-aspartate (NMDA) receptor encephalitis, which is second only to acute disseminated encephalomyelitis (ADEM) as a cause of immune-mediated encephalopathy and is four times more frequent a cause of encephalitis than are viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/49\">",
"     49",
"    </a>",
"    ]. Limbic encephalitis (LE) is the next most common type of autoimmune encephalopathy in children and is most often associated with voltage-gated potassium channel antibodies (VGKC). In a large series in children with probable immune encephalopathies, only 44 percent had positive antibodies. Of antibody-positive cases, 95 percent were accounted for NMDA (62 percent) and VGKC (33 percent); noLGI1 was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NMDA encephalitis is an autoimmune encephalitis characterized by a prolonged clinical course and a wide range of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/51\">",
"     51",
"    </a>",
"    ]. When severe, it mimics an infectious encephalitis with a flu-like prodrome, prominent seizures (often status epilepticus), delirium, and a progressive encephalopathy evolving to coma. In older patients, psychiatric symptoms are always noted, usually manifesting as psychosis that can evolve to catatonia. Seizures may also occur, but often to a lesser degree. As mental status improves, abnormal movement",
"    <span class=\"nowrap\">",
"     (dystonia/dyskinesias)",
"    </span>",
"    becomes prominent. Dystonia is seen more often than dyskinesias in young children. An autonomic storm often develops later in the course of the disease, resulting in",
"    <span class=\"nowrap\">",
"     hypoventilation/apnea",
"    </span>",
"    and cardiac standstill that may require intubation and cardiac pacing. The diagnosis is suspected in children and adolescents who present with the above symptoms. It is confirmed by the detection of antibodies to the NMDA receptor in serum or cerebrospinal fluid (CSF); CSF antibodies correlate better with clinical outcome than serum antibody levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370789#H3370789\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Anti-NMDA receptor encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to identify NMDA encephalitis because it may be associated with tumors and often responds to specific therapeutic interventions. NMDA encephalitis is associated with a neoplasm in approximately 30 percent of children and adolescents, and more often in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In girls and young women, an ovarian teratoma is the most common tumor. If a tumor is identified, its removal may hasten recovery. A first-line treatment is intravenous (IV)",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    with intravenous immunoglobulin (IVIG) or plasmapheresis. If no response is noted, given the protracted and severe course of the disease, aggressive immunomodulatory therapy should quickly follow with either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , given for months until recovery is established [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370789#H3370789\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Anti-NMDA receptor encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limbic encephalitis (LE) is an autoimmune encephalopathy phenotype characterized by memory loss and seizures, including status epilepticus and sleep and behavioral changes. The clinical symptoms are similar to those of NMDA encephalitis, with the exception of movement disorders that are not usually seen with LE. In children, LE is not typically associated with tumors except for anti-hu, which can be linked to neuroblastoma. MRI often shows high signal abnormalities in both medial temporal lobes. Electroencephalography (EEG) will show temporal spikes and seizure onset. Although in adults this association has been recently attributed to other synaptic proteins (eg, LGI1 or anti-CASPR-2), these associations have not been substantiated in pediatric studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/50,56\">",
"     50,56",
"    </a>",
"    ]. Other autoimmune antibodies linked to LE in children are anti-GAD, anti-hu (neuroblastoma), Gly2 and",
"    <span class=\"nowrap\">",
"     Ma1/2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. First-line treatments for LE are glucocorticoids, intravenous immunoglobulin (IVIG) and plasmapheresis, to which this disorder often responds more favorably than does NMDA encephalitis. Less often, more aggressive immunomodulatory therapy, as described for NMDA encephalitis, may be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H2380193#H2380193\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The autoimmune encephalopathies are diagnosed by measurement of specific antibodies in patients with suggestive symptoms. Most test panels for paraneoplastic antibodies include the most common associated antibodies, but some laboratories require that each antibody be ordered separately. All patients with suspected infectious encephalitis should also have testing for autoimmune antibodies, even if viral antigens are positive, as the two conditions occasionally coexist. The presence of Anti-Hu antibodies in a patient with LE should prompt an evaluation for neuroblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H3370796#H3370796\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Encephalitis and LGI1 antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=see_link&amp;anchor=H4565291#H4565291\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Others'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Initial treatment with glucocorticoids and IVIG should be considered in children with suspected autoimmune encephalopathy, regardless of whether the diagnosis is confirmed by antibody testing, because a beneficial response to treatment has been documented with or without the presence of specific antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/50\">",
"     50",
"    </a>",
"    ]. In a study in which over half of cases of suspected autoimmune encephalopathy were antibody-negative, 52 percent of children had a full recovery with treatment, whereas only 28 percent had similar outcome without treatment. Antibody confirmation is needed when considering long-term immune suppressive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28202936\">",
"    <span class=\"h2\">",
"     Reye syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reye syndrome is a rapidly progressive encephalopathy with hepatic dysfunction, which often begins several days after apparent recovery from a viral illness, especially varicella or influenza A or B [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Most cases occur in spring or winter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/60\">",
"     60",
"    </a>",
"    ]. It is characterized by vomiting and confusion, rapidly evolving to seizures and coma. Hepatomegaly is common, but icterus is usually mild or absent. Laboratory testing reveals markedly elevated aminotransferase activity, increased prothrombin time, hyperammonemia, hypoglycemia, and metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/59\">",
"     59",
"    </a>",
"    ]. The liver and other visceral organs have marked steatosis, and renal and cardiac failure may ensue. Increased intracranial pressure is an important contributor to the morbidity and mortality of Reye syndrome, and should be managed accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From a peak incidence in 1980 of 1 case per 100,000 children, rates of Reye syndrome fell dramatically following the identification of salicylate use as a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/61\">",
"     61",
"    </a>",
"    ] and advisories against use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    in febrile children, especially in cases with varicella or influenza (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\", section on 'Neurologic complications'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/62\">",
"     62",
"    </a>",
"    ]. Reye Syndrome is currently a rare occurrence with rates of one case per million children in the United States (1991 to 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of inborn errors of metabolism either predispose to Reye syndrome or are responsible for some cases of Reye-like syndrome. These include medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency and other fatty acid oxidation disorders, and urea cycle disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. It is possible that some of the apparent decline in Reye syndrome is due to improved diagnosis of these inborn errors or metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of Reye syndrome have been reported only rarely in association with salicylate treatment for Kawasaki disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/62/22506/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Similarly, there are scattered reports of Reye syndrome occurring during treatment with nonsteroidal antiinflammatory drugs for juvenile idiopathic arthritis or other connective tissue diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Other clinical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link&amp;anchor=H9#H9\">",
"     \"Kawasaki disease: Initial treatment and prognosis\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute toxic-metabolic encephalopathy (TME) is a condition of acute global cerebral dysfunction resulting in altered consciousness, behavior changes, or seizures that is not due to primary structural brain disease (eg, tumor or hemorrhage) or infection. TME usually is a consequence of systemic disorders, and, therefore, the causes are diverse. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite a wide array of pathophysiologic mechanisms, the clinical manifestations of TME tend to be very similar. Changes in mental status range from subtle cognitive difficulties to florid delirium. Motor abnormalities may include hypotonia or hypertonia, abnormal movements (myoclonic jerks, fine tremors, and asterixis), and generalized or focal seizures. Pupillary response and respiratory abnormalities depend on the underlying cause of the TME. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TME is a diagnosis of exclusion. Sepsis and meningitis, and structural abnormalities such as brain tumor or intracranial hemorrhage (especially shaken baby syndrome), must be excluded. Cultures of blood and cerebrospinal fluid should be performed to exclude infection, and head imaging performed to exclude structural causes of encephalopathy or head injury. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30974781\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory investigation of TME includes measurement of electrolytes, glucose, calcium and phosphate, tests of renal and hepatic function, arterial blood gases, lead levels, and toxicologic screening. Depending upon the clinical findings, blood and urine should be tested for inborn errors of metabolism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Important causes of TME are hypoxic-ischemic encephalopathy (eg, after drowning or airway obstruction), hypoglycemia or diabetic ketoacidosis, and electrolyte disturbances such as hypernatremia or hyponatremia, toxic ingestion of drugs (eg, sedatives, anticholinergic agents, and salicylates), or environmental toxins (eg, lead). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Specific etiologies of encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune encephalopathies &ndash; Symptoms suggestive of autoimmune encephalopathy (AE), especially when they occur suddenly are: refractory seizure disorder or status epilepticus (with or without fever), delirium, movement disorder or atypical psychiatric presentations (eg, hallucinations with delirium or seizures; insomnia). All cases of suspected infectious encephalitis should also have testing for autoimmune antibodies. A negative antibody panel does not exclude autoimmune encephalopathy, but antibody confirmation is needed when considering long-term immune suppressive treatment. (See",
"      <a class=\"local\" href=\"#H8032025\">",
"       'Autoimmune or paraneoplastic encephalitis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      NMDA encephalitis is mediated by antibodies to the N-methyl-D-aspartate receptor (NMDA). In young children it often mimics an infectious encephalitis. In adolescents, psychiatric manifestations are more common. Movement disorders, catatonia, and dysautonomia are often later findings that are more specific for NMDA encephalitis. The diagnosis is confirmed by the detection of antibodies to the NMDA receptor in serum or cerebrospinal fluid (CSF). It is important to identify NMDA encephalitis because it may be associated with tumors and often responds to specific therapeutic interventions.",
"     </li>",
"     <li>",
"      Limbic encephalitis (LE), an autoimmune encephalopathy phenotype, is characterized by memory loss, seizures, including status epilepticus with prominent temporal lobe abnormalities on magnetic resonance imaging (MRI) and electroencephalography (EEG). It is mostly linked to voltage-gated potassium channel (VGKC) antibodies; GAD, anti-hu (neuroblastoma),",
"      <span class=\"nowrap\">",
"       Ma1/2,",
"      </span>",
"      and Gly2 antibodies are also reported. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postinfectious encephalomyelitis is an immune-mediated encephalopathy that can occur after infection by viruses, including measles, varicella, and rubella, or after some immunizations. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Parainfectious encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264505280\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Edwin Myer, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Parke, JT. Acute encephalopathies. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2258.",
"    </li>",
"    <li>",
"     Posner JB, Saper CB, Schiff ND, Plum F. Diagnosis of stupor and coma, 4 Ed, Plum F, Posner JB.  (Eds), Oxford University Press, New York 2007.",
"    </li>",
"    <li>",
"     Earnest MP, Parker WD. Metabolic encephalopathies and coma from medical causes. In: Management of the Acutely Ill Neurological Patient, Grotta J (Ed), Churchill Livingstone, New York 1993. p.1.",
"    </li>",
"    <li>",
"     Young GB, DeRubeis DA. Metabolic encephalopathies. In: Coma and Impaired Consciousness, Young GB, Ropper AH, Bolton CF (Eds), McGraw-Hill, 1998. p.307.",
"    </li>",
"    <li>",
"     Bolton, CF, Young, GB. Uremic encephalopathy. In: Neurological Complications of Renal Disease, Bolton, CF, Young, GB (Eds), Buttersworth, Stoneham 1990. p.44.",
"    </li>",
"    <li>",
"     Chen R, Young GB. Metabolic encephalopathies. In: Baillere's Clinical Neurology, Bolton CF, Young GB (Eds), Balliere Tindall, London 1996. p.577.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/7\">",
"      Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/8\">",
"      Bates D. The management of medical coma. J Neurol Neurosurg Psychiatry 1993; 56:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/9\">",
"      Bleck TP, Smith MC, Pierre-Louis SJ, et al. Neurologic complications of critical medical illnesses. Crit Care Med 1993; 21:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/10\">",
"      Painter MJ, Alvin J. Neonatal Seizures. Curr Treat Options Neurol 2001; 3:237.",
"     </a>",
"    </li>",
"    <li>",
"     Plum F, Posner JB. The Diagnosis of Stupor and Coma, FA Davis Company, Philadelphia 1982. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/12\">",
"      American Academy of Pediatrics: Committee on Child Abuse and Neglect. Shaken baby syndrome: rotational cranial injuries-technical report. Pediatrics 2001; 108:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/13\">",
"      Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993; 33:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/14\">",
"      Eidelman LA, Putterman D, Putterman C, Sprung CL. The spectrum of septic encephalopathy. Definitions, etiologies, and mortalities. JAMA 1996; 275:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/15\">",
"      Kirkham FJ. Non-traumatic coma in children. Arch Dis Child 2001; 85:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/16\">",
"      Levy DE, Caronna JJ, Singer BH, et al. Predicting outcome from hypoxic-ischemic coma. JAMA 1985; 253:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/17\">",
"      Jacinto SJ, Gieron-Korthals M, Ferreira JA. Predicting outcome in hypoxic-ischemic brain injury. Pediatr Clin North Am 2001; 48:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/18\">",
"      Becker DJ, Ryan CM. Hypoglycemia: a complication of diabetes therapy in children. Trends Endocrinol Metab 2000; 11:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/19\">",
"      Glasgow JF, Middleton B. Reye syndrome--insights on causation and prognosis. Arch Dis Child 2001; 85:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/20\">",
"      White NH. Diabetic ketoacidosis in children. Endocrinol Metab Clin North Am 2000; 29:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/21\">",
"      Rosenbloom AL. Intracerebral crises during treatment of diabetic ketoacidosis. Diabetes Care 1990; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/22\">",
"      Cardenas JF, Bodensteiner JB. Osmotic demyelination syndrome as a consequence of treating hyperammonemia in a patient with ornithine transcarbamylase deficiency. J Child Neurol 2009; 24:884.",
"     </a>",
"    </li>",
"    <li>",
"     Cronan K, Kost SI. Renal and electrolyte emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher G, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.873.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/24\">",
"      Oddie S, Richmond S, Coulthard M. Hypernatraemic dehydration and breast feeding: a population study. Arch Dis Child 2001; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/25\">",
"      Conley SB. Hypernatremia. Pediatr Clin North Am 1990; 37:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/26\">",
"      Adrogu&eacute; HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/27\">",
"      De Petris L, Luchetti A, Emma F. Cell volume regulation and transport mechanisms across the blood-brain barrier: implications for the management of hypernatraemic states. Eur J Pediatr 2001; 160:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/28\">",
"      Strange K. Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992; 3:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/29\">",
"      Lee JH, Arcinue E, Ross BD. Brief report: organic osmolytes in the brain of an infant with hypernatremia. N Engl J Med 1994; 331:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/30\">",
"      Kahn A, Brachet E, Blum D. Controlled fall in natremia and risk of seizures in hypertonic dehydration. Intensive Care Med 1979; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/31\">",
"      Blum D, Brasseur D, Kahn A, Brachet E. Safe oral rehydration of hypertonic dehydration. J Pediatr Gastroenterol Nutr 1986; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/32\">",
"      Albanese A, Hindmarsh P, Stanhope R. Management of hyponatraemia in patients with acute cerebral insults. Arch Dis Child 2001; 85:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/33\">",
"      Arieff AI, Ayus JC, Fraser CL. Hyponatraemia and death or permanent brain damage in healthy children. BMJ 1992; 304:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/34\">",
"      Nishiyama S. Hypercalcemia in children: an overview. Acta Paediatr Jpn 1997; 39:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/35\">",
"      Kelly DA. Acute liver failure. Indian J Pediatr 1999; 66:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/36\">",
"      Alonso EM, Sokol RJ, Hart J, et al. Fulminant hepatitis associated with centrilobular hepatic necrosis in young children. J Pediatr 1995; 127:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/37\">",
"      Alper G, Jarjour IT, Reyes JD, et al. Outcome of children with cerebral edema caused by fulminant hepatic failure. Pediatr Neurol 1998; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/38\">",
"      Lockwood AH. Neurologic complications of renal disease. Neurol Clin 1989; 7:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/39\">",
"      S&aacute;nchez-Carpintero R, Narbona J, L&oacute;pez de Mesa R, et al. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001; 24:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/40\">",
"      Dietemann JL, Botelho C, Nogueira T, et al. [Imaging in acute toxic encephalopathy]. J Neuroradiol 2004; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/41\">",
"      Sandoval C, Kutscher M, Jayabose S, Tenner M. Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR Am J Neuroradiol 2003; 24:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/42\">",
"      Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/43\">",
"      Yip L, Dart RC, Gabow PA. Concepts and controversies in salicylate toxicity. Emerg Med Clin North Am 1994; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/44\">",
"      Clark I, Whitten R, Molyneux M, Taylor T. Salicylates, nitric oxide, malaria, and Reye's syndrome. Lancet 2001; 357:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/45\">",
"      Gleeson JG, duPlessis AJ, Barnes PD, Riviello JJ Jr. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: clinical features and risk of seizure recurrence. J Child Neurol 1998; 13:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/46\">",
"      Patchell RA. Neurological complications of organ transplantation. Ann Neurol 1994; 36:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/47\">",
"      Zwiener RJ, Ginsburg CM. Organophosphate and carbamate poisoning in infants and children. Pediatrics 1988; 81:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/48\">",
"      Trope I, Lopez-Villegas D, Cecil KM, Lenkinski RE. Exposure to lead appears to selectively alter metabolism of cortical gray matter. Pediatrics 2001; 107:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/49\">",
"      Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/50\">",
"      Hacohen Y, Wright S, Waters P, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/51\">",
"      Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/52\">",
"      Houtrow AJ, Bhandal M, Pratini NR, et al. The rehabilitation of children with anti-N-methyl-D-aspartate-receptor encephalitis: a case series. Am J Phys Med Rehabil 2012; 91:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/53\">",
"      Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/54\">",
"      Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/55\">",
"      Kashyape P, Taylor E, Ng J, et al. Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol 2012; 16:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/56\">",
"      Suleiman J, Brenner T, Gill D, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011; 76:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/57\">",
"      Haberlandt E, Bast T, Ebner A, et al. Limbic encephalitis in children and adolescents. Arch Dis Child 2011; 96:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/58\">",
"      Hurwitz ES, Nelson DB, Davis C, et al. National surveillance for Reye syndrome: a five-year review. Pediatrics 1982; 70:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/59\">",
"      Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct 2008; 26:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/60\">",
"      Sullivan KM, Belay ED, Durbin RE, et al. Epidemiology of Reye's syndrome, United States, 1991-1994: comparison of CDC surveillance and hospital admission data. Neuroepidemiology 2000; 19:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/61\">",
"      Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. N Engl J Med 1985; 313:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/62\">",
"      Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/63\">",
"      Smith ET Jr, Davis GJ. Medium-chain acylcoenzyme-A dehydrogenase deficiency. Not just another Reye syndrome. Am J Forensic Med Pathol 1993; 14:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/64\">",
"      Santer R, Schmidt-Sommerfeld E, Leung YK, et al. Medium-chain acyl CoA dehydrogenase deficiency: electron microscopic differentiation from Reye syndrome. Eur J Pediatr 1990; 150:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/65\">",
"      Schr&ouml;r K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs 2007; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/66\">",
"      Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992; 33:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/62/22506/abstract/67\">",
"      Wei CM, Chen HL, Lee PI, et al. Reye's syndrome developing in an infant on treatment of Kawasaki syndrome. J Paediatr Child Health 2005; 41:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6154 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22506=[""].join("\n");
var outline_f21_62_22506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Motor examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pupillary response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Respiratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30974781\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIFIC ETIOLOGIES OF ENCEPHALOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypoxic-ischemic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19643240\">",
"      - Inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fluid and electrolyte disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Organ failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hepatic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Uremic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Intoxications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Sedatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Salicylates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19642442\">",
"      - Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Environmental toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Parainfectious encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8032025\">",
"      Autoimmune or paraneoplastic encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28202936\">",
"      Reye syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264505280\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/63/38908\" title=\"table 1\">",
"      Laboratory findings inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 2\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20838?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=related_link\">",
"      Cerebral edema in children with diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19544?source=related_link\">",
"      Treatment and prognosis of coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_62_22507="Peroxisomal disorders";
var content_f21_62_22507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peroxisomal disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of peroxisome biogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zellweger syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal adrenoleukodystrophy (NALD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infantile Refsum disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhizomelic chondrodysplasia punctata type 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders with deficiency of a single peroxisomal enzyme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X-linked adrenoleukodystrophy, including adrenomyeloneuropathy (AMN) due to deficiency of adrenoleukodystrophy protein (ALDP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refsum disease (phytanoyl CoA hydroxylase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudo-NALD (acyl CoA oxidase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D-bifunctional enzyme deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dihydroxy-acetone phosphate acyltransferase (DHAP-AT) deficiency (RCDP type 2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkyl-DHAP synthase deficiency (RCDP type 3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-methylacyl-CoA racemase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acatalasemia (Catalase deficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22507=[""].join("\n");
var outline_f21_62_22507=null;
var title_f21_62_22508="Autoimmune disease Rx with IGIV";
var content_f21_62_22508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some autoimmune diseases for which IVIG has been used as an immunomodulator",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Autoimmune cytopenias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coagulopathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Arthritides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile&nbsp;idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graves disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatomyositis/polymyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin-dependent diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Recurrent spontaneous abortion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uveitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic Disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory/demyelinating neuropathies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intractable epilepsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myasthenia gravis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic autoimmune disease/vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            ANCA-associated vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyroglobulinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skin Deseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bullous diseases",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22508=[""].join("\n");
var outline_f21_62_22508=null;
var title_f21_62_22509="Definition and criteria for CKD";
var content_f21_62_22509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition and criteria for chronic kidney disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Chronic kidney disease is defined based on the presence of either kidney damage or decreased kidney function for three or more months, irrespective of cause.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration &ge;3 months, based on documentation or inference",
"       </td>",
"       <td>",
"        <p>",
"         Duration is necessary to distinguish chronic from acute kidney diseases.",
"        </p>",
"        <ul>",
"         <li>",
"          Clinical evaluation can often suggest duration",
"         </li>",
"         <li>",
"          Documentation of duration is usually not available in epidemiologic studies",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerular filtration rate (GFR) &lt;60 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         GFR is the best overall index of kidney function in health and disease.",
"        </p>",
"        <ul>",
"         <li>",
"          The normal GFR in young adults is approximately 125 mL/min/1.73 m",
"          <sup>",
"           2",
"          </sup>",
"          ; GFR &lt;15 mL/min/1.73 m",
"          <sup>",
"           2",
"          </sup>",
"          is defined as kidney failure",
"         </li>",
"         <li>",
"          Decreased GFR can be detected by current estimating equations for GFR based on serum creatinine (estimated GFR) but not by serum creatinine alone",
"         </li>",
"         <li>",
"          Decreased estimated GFR can be confirmed by measured GFR",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Kidney damage, as defined by structural abnormalities or functional abnormalities other than decreased GFR",
"       </td>",
"       <td>",
"        <p>",
"         Pathologic abnormalities (examples). Cause is based on underlying illness and pathology. Markers of kidney damage may reflect pathology.",
"        </p>",
"        <ul>",
"         <li>",
"          Glomerular diseases (diabetes, autoimmune diseases, systemic infections, drugs, neoplasia)",
"         </li>",
"         <li>",
"          Vascular diseases (atherosclerosis, hypertension, ischemia, vasculitis, thrombotic microangiopathy)",
"         </li>",
"         <li>",
"          Tubulointerstitial diseases (urinary tract infections, stones, obstruction, drug toxicity)",
"         </li>",
"         <li>",
"          Cystic disease (polycystic kidney disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         History of kidney transplantation. In addition to pathologic abnormalities observed in native kidneys, common pathologic abnormalities include the following:",
"        </p>",
"        <ul>",
"         <li>",
"          Chronic allograft nephropathy (non-specific findings of tubular atrophy, interstitial fibrosis, vascular and glomerular sclerosis)",
"         </li>",
"         <li>",
"          Rejection",
"         </li>",
"         <li>",
"          Drug toxicity (calcineurin inhibitors)",
"         </li>",
"         <li>",
"          BK virus nephropathy",
"         </li>",
"         <li>",
"          Recurrent disease (glomerular disease, oxalosis, Fabry disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Albuminuria as a marker of kidney damage (increased glomerular permeability, urine albumin-to-creatinine ratio [ACR] &gt;30 mg/g).*",
"        </p>",
"        <ul>",
"         <li>",
"          The normal urine ACR in young adults is &lt;10 mg/g. Urine ACR categories 10-29, 30-300 and &gt;300 mg are termed \"high normal, high, and very high\" respectively. Urine ACR &gt;2200 mg/g is accompanied by signs and symptoms of nephrotic syndrome (low serum albumin, edema and high serum cholesterol).",
"         </li>",
"         <li>",
"          Threshold value corresponds approximately to urine dipstick values of trace or 1+, depending on urine concentration",
"         </li>",
"         <li>",
"          High urine ACR can be confirmed by urine albumin excretion in a timed urine collection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Urinary sediment abnormalities as markers of kidney damage.",
"        </p>",
"        <ul>",
"         <li>",
"          RBC casts in proliferative glomerulonephritis",
"         </li>",
"         <li>",
"          WBC casts in pyelonephritis or interstitial nephritis",
"         </li>",
"         <li>",
"          Oval fat bodies or fatty casts in diseases with proteinuria",
"         </li>",
"         <li>",
"          Granular casts and renal tubular epithelial cells in many parenchymal diseases (non-specific)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Imaging abnormalities as markers of kidney damage (ultrasound, computed tomography and magnetic resonance imaging with or without contrast, isotope scans, angiography).",
"        </p>",
"        <ul>",
"         <li>",
"          Polycystic kidneys",
"         </li>",
"         <li>",
"          Hydronephrosis due to obstruction",
"         </li>",
"         <li>",
"          Cortical scarring due to infarcts, pyelonephritis or vesicoureteral reflux",
"         </li>",
"         <li>",
"          Renal masses or enlarged kidneys due to infiltrative diseases",
"         </li>",
"         <li>",
"          Renal artery stenosis",
"         </li>",
"         <li>",
"          Small and echogenic kidneys (common in later stages of CKD due to many parenchymal diseases)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Albumin-to-creatinine ratio (ACR) conversion factor 1.0 mg/g = 0.113 mg/mmol.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Levey A, Coresh J. Chronic kidney disease. Lancet 2011. DOI: 10.1016/S0140-6736(11)60178-5. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22509=[""].join("\n");
var outline_f21_62_22509=null;
var title_f21_62_22510="Asthma severity 5 to 11 yrs";
var content_f21_62_22510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51579%7EPULM%2F73634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51579%7EPULM%2F73634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;85 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = 60-80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC = 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 in 1 year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week but not more than once on each day",
"       </td>",
"       <td>",
"        &gt;2 days/week or multiple times on &le;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;1x/month",
"       </td>",
"       <td>",
"        &ge;2x/month",
"       </td>",
"       <td>",
"        &ge;2x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Lung function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        or peak flow",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        60-80 percent predicted/personal best",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;60 percent predicted/personal best",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        /FVC",
"       </td>",
"       <td class=\"sublist_other\">",
"        &gt;80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        75-80 percent",
"       </td>",
"       <td class=\"sublist_other\">",
"        &lt;75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22510=[""].join("\n");
var outline_f21_62_22510=null;
var title_f21_62_22511="Ilioinguinal iliohypogastric nerve block";
var content_f21_62_22511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Ilioinguinal iliohypogastric nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ultrasound transducer is placed superior and medial to the iliac spine on a line (shown in blue) marked from the anterior superior iliac spine to the umbilicus. A needle is inserted in the skin (red dot), and with ultrasound guidance, directed toward the ilioinguinal and iliohypogastic nerves, until a \"pop\" is felt as the needle pierces the external oblique fascia. Local anesthetic (0.25 to 0.5 percent bupivacaine or 0.5 to 0.75 percent ropivacaine) is administered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_62_22511=[""].join("\n");
var outline_f21_62_22511=null;
